0001493152-18-011665.txt : 20180814 0001493152-18-011665.hdr.sgml : 20180814 20180814120950 ACCESSION NUMBER: 0001493152-18-011665 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 181015600 BUSINESS ADDRESS: STREET 1: 11825 MAJOR STREET CITY: CULVER CITY STATE: CA ZIP: 90230 BUSINESS PHONE: 480-588-3333 MAIL ADDRESS: STREET 1: 11825 MAJOR STREET CITY: CULVER CITY STATE: CA ZIP: 90230 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-55203

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		45-1560906
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11825 Major Street, Culver City, California		90230
(Address of principal executive offices)		(Zip Code)

(310) 915-9700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

The number of shares of Common Stock, $0.001 per share par value, outstanding on August 13, 2018 was 174,114,818 shares.

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4	Controls and Procedures	25
PART II - OTHER INFORMATION
Item 1	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 2	Exhibits	25
Signatures		26

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

eWELLNESS HEALTHCARE CORPORATION

CONDENSED BALANCE SHEETS

	June 30, 2018			December 31, 2017
	(unaudited)

ASSETS

CURRENT ASSETS
Cash	$	9,083		$	6,882
Prepaid Expenses		171,570			179,827

Total current assets		180,653			186,709

Property & equipment, net		8,439			5,021
Intangible assets, net		12,477			13,954

TOTAL ASSETS	$	201,569		$	205,684

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	316,025		$	345,956
Accounts payable - related party		564,752			351,511
Accrued expenses - related party		218,000			210,828
Accrued compensation		1,120,960			1,071,369
Contingent liability		90,000			90,000
Convertible debt, net of discount		669,650			444,680
Derivative liability		376,951			1,140,578
Short term note and liabilities		-			180,051

Total current liabilities		3,356,338			3,834,973

Total Liabilities		3,356,338			3,834,973

COMMITMENTS AND CONTINGENCIES		-			-

STOCKHOLDERS’ DEFICIT
Preferred stock, authorized, 20,000,000 shares, $.001 par value, 0 shares issued and outstanding		-			-
Common stock, authorized 400,000,000 shares, $.001 par value, 165,856,760 and 142,352,406 issued and outstanding		165,857			142,352
Shares to be issued		14,800			-
Additional paid in capital		15,221,625			13,178,131
Accumulated deficit		(18,557,051	)		(16,949,772	)

Total Stockholders’ Deficit		(3,154,769	)		(3,629,289	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	201,569		$	205,684

The accompanying notes are an integral part of these condensed financial statements

eWELLNESS HEALTHCARE CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended						Six Months Ended
	June 30, 2018			June 30, 2017			June 30, 2018			June 30, 2017

OPERATING EXPENSES
Executive compensation		102,000			102,000			204,000			204,000
General and administrative		290,748			234,841			487,438			418,178
Professional fees		440,326			612,721			952,851			1,316,732

Total Operating Expenses		833,074			949,562			1,644,289			1,938,910

Loss from Operations		(833,074	)		(949,562	)		(1,644,289	)		(1,938,910	)

OTHER INCOME (EXPENSE)
Foreign exchange rate		692			24,691			8,091			37,404
Gain (loss) on derivative liability		(116,275	)		(843,038	)		393,477			4,399,596
Gain (loss) on extinguishment of debt		(43,131	)		-			(43,131	)		-
Interest expense		(139,891	)		(120,567	)		(319,800	)		(223,920	)

Net Income (Loss) before Income Taxes		(1,131,679	)		(1,888,476	)		(1,605,652	)		2,274,170

Income tax expense		(1,627	)		-			(1,627	)		(800	)

Net Income (Loss)	$	(1,133,306	)	$	(1,888,476	)	$	(1,607,279	)	$	2,273,370

Earnings (loss) per common share
Basic	$	(0.01	)	$	(0.02	)	$	(0.01	)	$	0.03
Diluted	$	(0.01	)	$	(0.02	)	$	(0.01	)	$	0.03

Weighted average shares outstanding
Basic		156,216,150			105,459,623			151,077,846			82,876,801
Diluted		156,216,150			105,459,623			151,077,846			85,564,942

The accompanying notes are an integral part of these condensed financial statements

eWELLNESS HEALTHCARE CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

	For Six Months Ended
	June 30, 2018			June 30, 2017

Cash flows from operating activies
Net income (loss)	$	(1,607,279	)	$	2,273,370
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		2,996			2,512
Contributed services		111,000			109,500
Shares issued for consulting services		250,700			94,150
Shares issued for contribution		70,000			-
Options expense		217,188			217,188
Amortization of debt discount to interest expense		239,710			176,296
Amortization of prepaids		126,992			789,994
Foreign currency exchange		8,091			-
Gain on derivative liability		(393,477	)		(4,399,596	)
Loss on extinguishment of debt		43,131			-
Changes in operating assets and liabilities
Prepaid expense		90,265			(43,752	)
Accounts payable and accrued expenses		38,572			22,583
Accounts payable - related party		213,241			17,169
Accrued expenses - related party		7,172			77,441
Accrued compensation		49,591			47,666

Net cash used in operating activities		(532,107	)		(615,479	)

Cash flows from investing activities
Purchase of equipment		(4,937	)		(2,910	)
Net cash used in investing activities		(4,937	)		(2,910	)

Cash flows from financing activities
Issuance of convertible debt		594,800			776,500
Payment on debt		(1,005	)		-
Debt issuance costs		(54,550	)		(110,550	)

Net cash provided by financing activities		539,245			665,950

Net increase in cash		2,201			47,561

Cash, beginning of period		6,882			13,995

Cash, end of period	$	9,083		$	61,556

Supplemental Information:
Cash paid for:
Taxes	$	1,267		$	800
Interest Expense	$	-		$	-
Non cash items:
Warrants issued with debt	$	-		$	86,730
Derivative liability and debt discount issued with new notes	$	219,526		$	155,885
Shares issued for debt conversion	$	569,999		$	3,220,392
Exercise of warrants	$	-		$	109,978
Shares issued for extinguishment of accounts payable	$	-		$	309,000
Shares issued for prepaids	$	209,000		$	278,500

The accompanying notes are an integral part of these condensed financial statements

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

Note 1. The Company

The Company and Nature of Business

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated no revenues to date.

eWellness is the first physical therapy telehealth company to offer insurance reimbursable real-time distance monitored treatments. Our business model is to license our PHZIO (“PHZIO”) platform to any physical therapy (“PT”) clinic in the U.S. and or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program. The Company’s PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries. PHZIO re-defines the way physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as: Anthem Blue Cross and Blue Shield.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2018. The unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

Going Concern

For the six months ended June 30, 2018, the Company had no revenues. The Company has an accumulated loss of $18,557,051. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

Fair Value of Financial Instruments

As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	376,951	$	-	$	-	$	376,951
Total Liabilities measured at fair value	$	376,951	$	-	$	-	$	376,951

As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	1,140,578	$	-	$	-	$	1,140,578
Total Liabilities measured at fair value	$	1,140,578	$	-	$	-	$	1,140,578

Note 3. Related Party Transactions

During the six months ended June 30, 2018, a company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, invoiced the Company $10,430 for accounting services. The amount outstanding as of June 30, 2018 and December 31, 2017 was $1,920 and $700, respectively.

In April 2015, the Company entered into an operating agreement with a physical therapy company (“EPT”) which is owned by the Company’s President and Chief Executive Officer. Through the agreement, the Company agrees to provide operating capital advances for EPT to offer the Company’s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPT shall be allocated monthly. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.

In November 2016, the Company signed an agreement with a programming company (“PC”) within which one of the Company’s directors and Chief Technical Officer is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHIZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company’s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHIZIO platform. The agreement establishes that the Company is indebted to the PC for $225,000 for past programming services. For this amount, the Company issued 25,280,899 common shares at a value of $0.0089 per share on April 1, 2017. The PC will also have the right to appoint 40% of the directors. At the end of June 30, 2018, the Company had a payable of $562,832 due to this company.

The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Statement of Operations and Additional Paid in Capital in the Balance Sheet.

Throughout the period ended June 30, 2018, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2018 and December 31, 2017 were $0 and $5,828, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $218,000 and $205,000 at June 30, 2018 and December 31, 2017, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $1,120,960 and $1,071,369 at June 30, 2018 and December 31, 2017 respectively.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

Note 4. Non-Convertible Notes Payable

In February 2017, the Company was served by a complaint filed by the holder of a note payable. The action was removed from Louisiana state court to the United States Federal District Court in Baton Rouge, LA. The lawsuit alleges that the Company is indebted to the note holder a promissory note stemming from four loans to the Company during the 20 months prior to February 2017 amounting to $75,500 in total original principal bearing interest at 12% per annum, of which $45,202 has been repaid. Further, the note holder claims that, because of alleged defaults and extensions of the notes, the Company is now indebted in the amount of $253,877 inclusive of interest and penalties at an effective rate exceeding 70% per annum, far more than the maximum rate allowable in California or Louisiana. The Company and its counsel have determined that: (i) the note holder is not a licensed lender in the State of California, where the loan was made and the $75,500 was deposited and therefore was not permitted under California law to make loans in the State; and (ii) the interest rate the note holder is seeking to collect is usurious and therefore interest claimed in the lawsuit is neither collectible nor enforceable. In October 2017 the complainant and his counsel motioned to dismiss the unlicensed lender assertion. In January 2018 the U.S. District Court, Louisiana ruled that the unlicensed lender assertion was to proceed. The Company and counsel believe that the suit is wholly without merit and the company will prevail.

On June 20, 2018, a settlement agreement was signed between the Company and holder of the note payable with the following terms for the cancellation of the note payable, accrued interest and warrants:

	1.	The Company will issue 2,709,444 shares of commons stock that is immediately tradeable under Securities and Exchange Commission Rule 144, but subject to a daily trading limit of 25,000 shares per day;
	2.	The Company will issue 1,290,556 shares of common stock that shall be subject to a 180-day holding period and are also subject to a daily trading limit of 25,000 shares per day;
	3.	The holder of the note payable shall bear all fees and expenses, including attorneys’ fees, associated with the transfer and trading of the Company’s shares;
	4.	Beyond issuing the shares noted above, the Company shall not take any additional action that would cause the note holder to incur tax consequence from the transfer or would affect the note holder’s tax consequences in any way.

The Company issued the 4,000,000 shares of common stock on June 20, 3018. At June 30, 2018, the Company had no indebtedness to this holder of the note payable principal or accrued interest. During the six months ended June 30, 2018 and 2017, the Company accrued interest expense totaling $15,183 and $16,071, respectively.

Note 5. Convertible Notes Payable

In January 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $110,000. The note, which is due on October 12, 2018 has an original issue discount of $10,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.20 or (ii) 65% of the lowest per share trading price for the fifteen (15) trading days prior to the conversion date. Conversion into shares of common stock can commend immediately following the 180^th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $4,099.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

In January 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $91,300. The note, which is due on October 30, 2018, has an original issue discount of $8,300. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock can commence immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $5,073.

In February 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $63,800. The note, which is due on November 30, 2018, has an original issue discount of $5,800. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock can commence immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,853.

In March 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $77,000. The note, which is due on December 5, 2018, has an original issue discount of $7,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the average of the three daily VWAPs for the trading price for the twenty (20) trading days before the 181^stcalendar date of the note or the ten (10) trading days if after the 181^st calendar day of the note. During the six months ended June 30, 2018, the Company recognized interest expense of $1,975. As of June 30, 2018, the institutional investor exercised its MFN provision in Paragraph 4a increasing the OID from the stated in the note from 10% to 15% thus increasing the amount owed to $80,500.

In March 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $72,450. The note, which is due on December 30, 2018, has an original issue discount of $9,450. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,453.

In May 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $125,000. The note, which is due on May 10, 2019, has an original issue discount of $3,750. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock at a price equal to 72% of the lowest VWAP for the ten (10) trading days prior to and including the conversion date. Conversion into shares of common stock can commence following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $1,370.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

In May 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $51,750. The note, which is due on March 1, 2019, has an original issue discount of $6,750. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to and including the conversion date. Conversion into shares of common stock can commence following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $612.

Note 6. Equity Transactions

Common Stock

In January 2018, the Board of Directors approved the extension of an Advisory Agreement dated February 15, 2015 for one year. The Company issued 800,000 shares of common stock as compensation with a value of $104,000. This value is being amortized over the life of the contract.

During the six months ended June 30, 2018, the Company agreed to issue a total of 200,000 shares of common stock for consulting services at a value of $14,800. At the end of June 30, 2018, these shares had not yet been issued and are recorded in Shares to be Issued.

During the six months ended June 30, 2018, the Company issued a total of 13,654,354 shares of common stock per debt conversion of convertible notes dated April, July, September and December 2017. The total of the debt conversion was $569,998 which includes $19,776 of accrued interest.

During the six months ended June 30, 2018, the Company issued 2,550,000 shares of common stock for marketing and consulting services valued at $235,900.

During the six months ended June 30, 2018, the Company issued 4,000,000 shares of common stock for settlement of a complaint filed in the United States Federal District Count (see Footnote 4). The debt settled totaled $236,868 which includes $56,817 of accrued interest.

In June 2018, the Company entered into a consulting agreement within which the Company agreed to issue 125,000 shares of common stock per month beginning in July 2018 and 1,500,000 shares of common stock upon signing of the agreement. The 1,500,000 shares of common stock were issued with a value of $105,000 which is being amortized over the life of the contract.

In June 2018, the Company executed an Equity Purchase Agreement with an institutional investor within which the investor agrees to purchase up to $1,500,000 of the Company’s common stock, par value $0.001. As an inducement to the investor to enter into the agreement, the Company issued 1,000,000 restricted shares of common stock to the investor valued at $70,000.

In January 2018, the Board of Directors agreed to form an eWellness Healthcare Corporation 2018 Equity Incentive Plan (“Plan”). The Plan shall be for 20,000,000 shares of common stock that will be placed in a 10b5-1 Sales Plan that will be registered under an S-8 Registration Statement. Under the sales plan, each recipient will open an account with Garden State Securities (“GSS”) for management of all sales of shares issued under the Plan. Quarterly limitations are placed on the number of shares that can be sold. The Company initially allocated 17,400,000 shares to officers, directors and consultants. As of June 30, 2018, no shares have been issued.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

Stock Options

The following is a summary of the status of all Company’s stock options as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of Stock		Average Exercise		Remaining		Intrinsic
	Options		Price		Life (yrs)		Value
Outstanding at December 31, 2017		20,000,000	$	0.26		1.9	$	-
Granted		-		-
Exercised		-		-
Cancelled		-		-
Outstanding at June 30, 2018		20,000,000		0.26		1.8	$	-
Options exercisable at June 30, 2018		16,398,958	$	0.28		1.8	$	-

The Company recognized stock option expense of $217,188 and $217,288 for the six months ended June 30, 2018 and 2017.

Warrants

In March 2018, the Board of Directors, at the request and with the approval of the investors, determined that it was in the best interests of the Company and the Investors, based upon market price and relatively limited liquidity of the shares of common stock that the Company revised the expiration date and exercise price for 417,429 unexercised warrants granted on April 9, 2015. The original expiration date of April 9, 2018 is extended to April 9, 2019. The original exercise price of $.35 is reduced to $.05.

In February 2017, the Company authorized the issuance of 68,750 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $5,932.

In April 2017, the Company authorized the issuance of 1,232,000 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $106,732.

The following is a summary of the status of the Company’s warrants as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of		Average Exercise		Remaining		Intrinsic
	Warrants		Price		Life (yrs.)		Value
Outstanding at December 31, 2017		8,753,179	$	0.21		2.4	$	0.038
Granted		417,429	$	0.05		1.0		-
Exercised		-		-		-		-
Cancelled		3,217,429	$	0.05		1.0		-
Outstanding at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038
Warrants exercisable at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

For purpose of determining the fair market value of the warrants and options outstanding at June 30, 2018, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessarily as of the reporting date. The assumptions used in the Black Scholes valuation of the date of issuance are as follows:

Stock price on the valuation date	$	.0673-.089
Exercise price of warrants	$	.004 and .25
Dividend yield		0.00	%
Years to maturity		3-4
Risk free rate		2.33%-2.68	%
Expected volatility		245.23%-257.73	%

Note 7. Commitments, Contingencies

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.

The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”).

Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.

Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419 but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

Because of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. Because of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.

Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining currently the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. Considering the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.

From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Note 8. Derivative Valuation

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favored Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2018 and 2017, the Company amortized the debt discount of $239,710 and $82,443, respectively. The derivative liability is adjusted periodically according to stock price fluctuations and other inputs and was $376,951 and $1,140,578 at June 30, 2018 and December 31, 2017, respectively.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

During the six months ended June 30, 2018, the Company had the following activity in the derivative liability account:

	Total
Derivative liability at December 31, 2017	$	1,140,578
Addition of new conversion option derivatives		91,283
Extinguishment due to note conversions		(258,823	)
Extinguishment due to note cancellations		(202,610	)
Changes in fair value		(393,477	)
Derivative liability at June 30, 2018	$	376,951

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

Stock price at valuation date	$	.0725-.089
Exercise price of warrants	$	.004 - .25
Conversion rate of convertible debt	$	.0495 – 0.2000
Risk free interest rate		1.93%-2.68	%
Stock volatility factor		110.9%-257.73	%
Years to Maturity		.08 – 4
Expected dividend yield		None

Note 9. Subsequent Events

In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 17, 2019 has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note.

In July 2018, the Company executed an 3% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $180,000 for funding in three tranches. The note, which is due twelve months from the date of each individual tranche, has an original issue discount of $10,000 per tranche. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to 75% of the market price which is lowest trading price during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The trading price is the lesser of: (i) lowest traded price or (ii) the lowest closing bid price on the OTCQB. The first tranche of $60,000 was received in the month of July.

In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $28,250. The note, which is due on April 17, 2019 has an original issue discount of $3,250. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note. The Company issued 50,000 shares of common stock valued at $4,000 upon the execution of this note.

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

June 30, 2018

(unaudited)

In July 2018, the Company entered into a consulting services agreement with a consultant for one year for a monthly fee of $5,000.

In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 30, 2019 has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average VWAP for the ten(10) trading day period ending on the latest compete trading day prior to the conversion date. The Company issued 100,000 shares of common stock valued at $8,000 upon execution of this note.

During the month of July to the filling of this report, the Company has issued 700,000 shares of common stock for consulting services valued at $52,775.

During the month of July to the filing of this report, the Company issued 7,408,058 shares of common stock for conversion of convertible debt valued at $369,843 which includes $138,983 of accrued interest and default fees.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward-looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our future revenues and financial performance; risks associated with product development and technological changes; the acceptance of our products in the marketplace by potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the six months ended June 30, 2018 and 2017 and should be read in conjunction with such financial statements and related notes included in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

THE COMPANY

Overview

eWellness is the first physical therapy telehealth company to offer insurance reimbursable real-time distance monitored treatments. eWellness plans to generate revenue from Third Party Healthcare Administrators (“TPA”) employees, PTs and corporate wellness licensees on a contractually recurring PHZIO session fee basis. Our PHZIO platform is anticipated to transform the access, cost and quality dynamics of physical therapy (“PT”) delivery for the market participants. eWellness further believes any patient, employer, health plan or healthcare professional interested in a better approach to PT is a potential PHZIO platform user.

Our PHZIO platform completely disrupts the current in-clinic business model of the $30 billion PT industry. Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current access to PT clinics. eWellness’ underlying technology platform is complex, deeply integrated and purpose-built over the past four years for the evolving PT marketplace. eWellness’ PHZIO platform is highly scalable and can support substantial growth of third party licensees. eWellness’ PHZIO platform provides for broad interconnectivity between PT practitioners and their patients, uniquely positioning the Company as a focal point in the rapidly evolving PT industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home care.

The Company’s PHZIO home PT exercise platform has been designed to disrupt the $30 billion PT and the $8 billion corporate wellness industries. PHZIO re-defines the way PT can be delivered. PHZIO is the first real-time remote monitored one-to-many PT platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as Anthem Blue Cross and Blue Shield.

Los Angeles Sales & Marketing Office: The Company opened its first sales and marketing office in Playa Vista, California in May 2017 to accelerate the adoption of PHZIO and the other new digital telehealth tools to patients, physicians and PT’s in California. The company will also be hiring sales and marketing professionals to manage the new silos of business.

eWellness will initially rollout these new telehealth solutions within California, New York and Virginia, with plans to expand nationally over the next 6 months. With these new telehealth tools, eWellness will engage with the “At-Home” Physical Therapy treatment market. This market involves physical therapy practitioners treating patients in their home instead of a clinic. The “At-Home” market model when combined with PHZIO offers patients and practitioners a means to receive and deliver PT services without having to leave work during normal business hours. Patients will be able to receive physical therapy services at almost any hour of the day. A model that is not currently employed within traditional clinical settings.

Plan of Operations

Our business model is to license our PHZIO (“PHZIO”) platform to any physical therapy (“PT”) clinic in the U.S. and or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program.

The Company’s 5-Year Agreement with Endeavor Plus. In October 2017 eWellness executed a 5-year Comprehensive Physical Therapy Services Agreement with Endeavor Plus Services, Inc. (“EPS”), a fast-growing healthcare plan administrator. EPS projects having approximately 100,000 healthcare members in 2018. This level of sales will allow the Company to gain cash flow positive operations during the second half of 2018. Additionally, if EPS can continue their projected growth rate over the next 12-18 months an additional 500,000 new members would be added. Endeavor Plus, Inc. (“EPI”), the parent company of EPS, has taken the lead in a movement to assist small group employers to leave fully insured health plans and use partially self-funded ERISA qualified health insurance plans that are new and innovative and embrace a new era of Consumer-Driven Health Care Planning (CDHC). EPI’s mission is to bring about innovative changes using existing law and regulations to change the traditional health insurance models to drive down healthcare costs while offering significantly better benefits to both small and midsize group employers and their employees. This is accomplished further by having these employers and their employees to participate in the Endeavor Plus Plan, a CDHC program with technology-driven health care programs that are affordable, manageable and responsive to the demand for higher quality care with cost transparency, integrated health information and better provider access and communication and better outcomes.

EPS/PHZIO Marketing Plans. eWellness and EPS intend to immediately commence system, sales and marketing integration, to position eWellness to begin onboarding and treating EPS members in the second quarter of 2018. EPS is a third-party administrator (TPA), which is an organization that processes insurance claims or certain aspects of employee benefit plans for small and medium sized companies. EPS is projecting to grow rapidly in the small group health insurance market which has annual premiums of over $384 billion. Approximately 84% of this market is traditional full insurance. EPS is expected to grow rapidly by offering these small employers the ability to self- insure through excellent plan design and reinsurance. The Company is excited to be chosen as their PT gatekeeper as well as wellness program supplier. Our comprehensive PT & wellness programs and consulting services are anticipated to provide EPS with new products that will: (1) build new sales channels that increase their current health insurance business, and (2) create new revenue sources through the introduction of such products.

The Company Partnership with LifeWallet (“LW”) In February 2018 the Company signed a Partnership Agreement to co-market the Company’s PHZIO platform with LW (https://www.lifewallet.com) which provides employers, communities and healthcare professionals with a simple, consumer centric, integrated platform to assess the health of their population and monitor their progress towards better health. LifeWallet™ is transforming the delivery of care and revolutionizing the health care to wellness process with a consumer centric health platform and modern digital assistants that promote better outcomes. LW’s employees are dedicated to making the best products on earth. LWt™ is creating a one of a kind technology region in the south and has brought in developers from leading technology companies including Apple.

Concierge PT Medical Service. The Company will be provisioning to EPS and/or LW insureds a new and highly unique patient treatment protocol that includes “white glove” concierge in-home or in-office PT assessments and digital care treatments to enhance the medical treatment and help improve patient treatment outcomes. The Company will become the exclusive provider of “white glove” concierge in-home or in-office PT assessments, digital physical therapy and a wellness program to the individuals covered by EPS and or LW. The Company has been selected to be the gatekeeper for all EPS and or LW PT treatments. As the PT treatment gatekeeper, the Company will conduct an online consultation with each patient to assess the complexity involved with the patient presentation. From the online consultation, an in-home or in-office evaluation of the patient may be prescribed. Through this initial evaluation, a plan of care will be designed for each patient that in most cases is anticipated to include digital therapy sessions.

PreHabPT. Any individuals covered by EPS and/or LW, who are seeking non-emergency orthopedic surgery shall first receive a concierge online consultation, in-home or in-office PT therapy evaluation and will be prescribed a four to eight-week prehabpt.com exercise program prior to any surgery. Another in-home or in-office PT evaluation will be made following surgery and a treatment plan will be initiated. PreHabPT is up to an eight-week physician to patient pre-surgical (Prehab) digital therapeutic exercise treatment system for patients that anticipate having total join replacement (knee, hip and or shoulder) or back surgeries.

PurePT. PurePT is a patient and independent PT digital treatment platform for connecting new patients to PT’s that are seeking to be treated with our PHZIO treatment system. Patient program assessments can be made in the privacy of a patient’s home or office. PurePT connects new patients to PT’s, particularly in states that have direct access rules where patient’s insurance will reimburse for treatment without requiring a physician’s prescription. PurePT puts the patient first.

PHZIO Comprehensive Wellness Program Any EPS and/or LW insureds may, after an in-home or in-office PT assessment, enroll in a 6-month comprehensive wellness program. The top line wellness goals of our PHZIO wellness exercise program is to graduate at least 60% of inducted patients through our 6-month program. Patients should expect to experience an average of a 20% reduction in BMI, a two-inch reduction in waist size, weight loss of at least 10 pounds, significant overall improvement in balance, coordination, flexibility, strength and lumbopelvic stability. Patients also should score better on Functional Outcomes Scales (Oswestry and LEFS) which indicates improved functional activity levels due to reduced low back, knee and hip pain.

The Company’s PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries. PHZIO re-defines the way physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as: Anthem Blue Cross, AETNA and Blue Shield.

The PHZIO Solution: A New Physical Therapy Delivery System

●	SaaS technology platform solution for providers bundling rehabilitation services and employer wellness programs;

●	First real-time remote monitored 1-to-many physical therapy treatment platform for home use;

●	Ability for physical therapists to observe multiple patients simultaneously in real-time;

●	Solves what has been a structural problem and limitation in post-acute care practice growth.

●	PT practices can experience 20% higher adherence & compliance rates versus industry standards; and

●	Tracking to 30% increase in net income for a PT practice.

Our initial PHZIO platform enables employees or patients to engage with live or on-demand video based physical therapy telemedicine treatments from their home or office. Following a physician’s exam and prescription for physical therapy to treat back, knee or hip pain, a patient can be examined by a physical therapist and if found appropriate inducted in the Company’s PHZIO program that includes a progressive 6-month telemedicine exercise program (including monthly in-clinic checkups). All PHZIO treatments are monitored by a licensed therapist that sees everything the patient is doing while providing their professional guidance and feedback in real-time. This ensures treatment compliance by the patient, maintains the safety and integrity of the prescribed exercises, tracks patient metrics and captures pre-and post-treatment evaluation data. PHZIO unlocks a host of potential for revolutionizing patient treatment models and directly links back to the established brick and mortar physical therapy clinic. This unique model enables any physical therapy practice to be able to execute more patient care while utilizing their same resources and creates more value than was ever before possible.

Our PHZIO platform, including: design, testing, exercise intervention, follow-up, and exercise demonstration, has been developed by accomplished Los Angeles based physical therapist Darwin Fogt. Mr. Fogt has extensive experience and education working with diverse populations from professional athletes to morbidly obese. He understands the most beneficial exercise prescription to achieve optimal results and has had enormous success in motivating all patient types to stay consistent in working toward their goals. Additionally, his methods have proven effective and safe as he demonstrates exercises with attention to proper form to avoid injury. Mr. Fogt has established himself as a national leader in his field and has successfully implemented progressive solutions to delivering physical therapy: he has consulted with and been published by numerous national publications including Runner’s World, Men’s Health, Men’s Journal, and various Physical Therapy specific magazines; his 13 plus years of experience include rehabilitating the general population, as well as professional athletes, Olympic gold medalists, and celebrities. He has bridged the gap between physical therapy and fitness by opening Evolution Fitness, which uses licensed physical therapists to teach high intensity circuit training fitness classes. He also founded one of the first exclusive prenatal and postnatal physical therapy clinic in the country. Mr. Fogt is a leader in advancing the profession to incorporate research-based methods and focus on, not only rehabilitation but also wellness, functional fitness, performance, and prevention. He can recognize that the national healthcare structure (federal and private insurance) is moving toward a model of prevention and that the physical therapy profession will take a larger role in providing wellness services to patients.

Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current access to physical therapy clinics.

Our underlying technology platform is complex, deeply integrated and purpose-built over the three years for the evolving physical therapy marketplace. Our PHZIO platform is highly scalable and can support substantial growth of third party licensees. Our PHZIO platform provides for broad interconnectivity between PT practitioners and their patients and, we believe, uniquely positions us as a focal point in the rapidly evolving PT industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home care.

We plan to generate revenue from third-party PT and corporate wellness licensees on a contractually recurring per PHZIO session fee basis. Our PHZIO platform is anticipated to transform the access, cost and quality dynamics of physical therapy delivery for all the market participants. We further believe any patient, employer, health plan or healthcare professional interested in a better approach to physical therapy is a potential PHZIO platform user.

Before even launching, we have received a high indication of interest in our service. We think the demand is warranted but recognize that in the preliminary stages of our services, we may experience bottlenecks in our ability to meet the demand for same. Under this type of environment, it is critical to maintain awareness of the Company’s operational budget goals and how they are being met in our attempts to address demand. Regardless of our growth pace, it is critical to shareholder value that we are mindful of our operational spending.

Investment Agreement with Tangiers Global, LLC

In February 2017, the Company entered into an Investment Agreement with Tangiers. Pursuant to the terms of the Investment Agreement, Tangiers committed to purchase up to $5,000,000 of the Company’s common stock over a period of up to 36 months. From time to time during the 36-month period commencing from the effectiveness of the registration statement, we may deliver a put notice to Tangiers which states the dollar amount that we intend to sell to Tangiers on a date specified in the put notice. The maximum investment amount per notice must be no more than 200% of the average daily trading dollar volume of our Common stock for the ten (10) consecutive trading days immediately prior to date of the applicable put notice and such amount must not exceed an accumulative amount of $250,000. The minimum put amount is $5,000. The purchase price per share to be paid by Tangiers will be the 80% of the of lowest trading prices of the Common stock during the 5 trading days including and immediately following the date on which put notice is delivered to Tangiers.

In connection with the Investment Agreement with Tangiers, we also entered into a registration rights agreement with Tangiers.

Advisory Agreement with Fintech Global Consultants

In March 2018, the Company signed an Advisory Agreement with Fintech Global Consultants [“FGC” http://f-g-c.com] to assist the Company in completing blockchain adaptation across the $30 billion physical therapy and $8 billion wellness markets with new advanced health tech tools. We believe that out implementation of the new blockchain technology for the Company’s PHZIO digital treatment platform and our other new health tech tools may have a beneficial impact on patient care beginning in the third quarter of 2018. The Company has hired a leading international blockchain advisory firm to further our state of the art PHZIO digital telehealth platform. We believe that by being blockchain enabled, our patients will have more convenient access to wellness services, seamless storage and access to HIPPA compliant medical records and simplified insurance reimbursement. In addition, FGC will assist the Company in its planned Initial Coin Offering of up to a $10 million non-dilutive funding that we believe will help in the implementation and acceleration of PHZIO’s expansion on a national basis during the next twelve months.

Results of Operations for the three and six months ended June 30, 2018 and 2017

REVENUE: We had no revenues from operations during the six months ended June 30, 2018 and 2017. We expect to generate revenues during the fourth quarter of 2018.

OPERATING EXPENSES: Total operating expenses decreased to $1,644,289 for the six months ended June 30, 2018 from $1,938,910 for the six months ended June 30, 2017. The decrease resulted from a reduction in consultant expense. Total operating expenses decreased to $833,074 for the three months ended June 20, 2018 from $949,562 for the three months ended June 30, 2017. The decrease resulted from a reduction in consultant expense.

NET LOSS: The Company incurred a net loss of $1,607,279 for the six months ended June 30, 2018, compared with a net income of $2,273,370 for the six months ended June 30, 2018. The significant decrease from income to loss was the result of a decrease in the revaluation of the derivative liabilities for the convertible debt and warrants totaling $4,006,119 and an increase in interest expense. For the three months ended June 30, 2018, the Company incurred a loss 1,133,306 compared with a loss of $1,888,476 for the three months ended June 30, 2017. The decrease in the loss was the result of a decrease in the revaluation of the derivative liabilities for the convertible debt and warrants totaling $726,763 offset by an increase in interest expense.

Liquidity and Capital Resources

As of June 30, 2018, we had negative working capital of $3,175,685 compared to negative working capital of $3,648,264 as of December 31, 2017. The decrease resulted from a decrease in the derivative liability and reduction of short term note payable offset by an increase in convertible debt. Cash used in operations was $532,107 and $615,479 for the six months ended June 30, 2018 and 2017, respectively. The decrease in cash used in operations was because of the relative changes in the assets and liabilities. Cash used in investing activities was $4,937 and $2,910 for the six months ended June 30, 2018 and 2017, respectively. Cash flows provided by financing activities were $539,245 and $665,950 for the six months ended June 30, 2018 and June 30, 2017, respectively. The decrease in cash flows from financing activities was a reduction in the issuance of convertible debt for cash. The cash balance as of June 30, 2018 was $9,083.

We believe that anticipated cash flows from operations will be insufficient to satisfy our ongoing capital requirements. We are seeking financing in the form of equity capital to provide the necessary working capital. Our ability to meet our obligations and continue to operate as a going concern is highly dependent on our ability to obtain additional financing. We cannot predict whether this additional financing will be in the form of equity or debt or be in another form. We may not be able to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. In any of these events, we may be unable to implement our current plans which circumstances would have a material adverse effect on our business, prospects, financial conditions and results of operations.

Contingencies

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

As disclosed in the prior amendments to the Initial Form 8-K, we have filed the prior amendments in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to the Company’s potential violation of Rule 419. Although the Company has continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, based upon latest communications with the persons reviewing the Form 8-K, they do not agree with the assessments the Company presented to them. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible now to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining now the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. Considering the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.

Capital Expenditure Plan

During the three months ended June 30, 2018, we raised $414,550, less $46,550 for debt issuance costs, in equity and debt capital and we may require up to an additional $1.6 million in capital during the next 12 months to fully implement our business plan and fund our operations. Our plan is to utilize the equity capital that we raise, together with anticipated cash flow from operations, to fund a very significant investment in sales and marketing, concentration principally on advertising and incentivizing existing customers for the introduction of new customers, among other strategies. However, there can be no assurance that: (i) we will continue to be successful in raising equity capital in sufficient amounts and/or at terms and conditions satisfactory to the Company; or (ii) we will generate sufficient revenues from operations, to fulfill our plan of operations. Our revenues are expected to come from our PHZIO platform services. As a result, we will continue to incur operating losses unless and until we are able to generate sufficient cash flow to meet our operating expenses and fund our planned sales and market efforts. There can be no assurance that the market will adopt our portal or that we will generate sufficient cash flow to fund our enhanced sales and marketing plan. In the event that we are not able to successfully: (i) raise equity capital and/or debt financing; or (ii) market and significantly increase the number of portal users and revenues from such users, our financial condition and results of operations will be materially and adversely affected and we will either have to delay or curtail our plan for funding our sales and marketing efforts.”

Off-Balance Sheet Arrangements

As of June 30, 2018 and December 31, 2017, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.

Contractual Obligations and Commitments

In February 2017, the Company was served by a complaint filed by a holder of a note payable. The action was removed from Louisiana state court to the United States Federal District Court in Baton Rouge, LA. The lawsuit alleges that the Company is indebted to Schoemann under a promissory note stemming from four loans to the Company during the 20 months prior to February 2017 amounting to $75,500 in total original principal bearing interest at 12% per annum, of which $45,202 has been repaid. Further the note holder claims that, because of alleged defaults and extensions of the notes, the Company is now indebted in the amount of $253,677 inclusive of interest and penalties at an effective rate exceeding 70% per annum, far in excess of the maximum rate allowable in California or Louisiana. The Company and its counsel have determined that: (i) note holder is not a licensed lender in the State of California, where the loan was made and the $75,500 was deposited and therefore was not permitted under California law to make loans in the State; (ii) the interest rate the note holder is seeking to collect is usurious and therefore interest claimed in the lawsuit is neither collectible nor enforceable. In October 2017 the complainant and his counsel motioned to dismiss the unlicensed lender assertion. In January 2018 the U.S. District Court, Louisiana ruled in favor of the Company that the unlicensed lender assertion made by the Company and counsel was to proceed in a matter brought before the court by note holder Rodney Schoeman on January 24, 2017. The Company and counsel believe that the Schoemann suit is wholly without merit and the Company will prevail.

	o	The Company will issue 2,709,444 shares of commons stock that is immediately tradeable under Securities and Exchange Commission Rule 144, but subject to a daily trading limit of 25,000 shares per day;
	o	The Company will issue 1,290,556 shares of common stock that shall be subject to a 180-day holding period and are also subject to a daily trading limit of 25,000 shares per day;
	o	The holder of the note payable shall bear all fees and expenses, including attorneys’ fees, associated with the transfer and trading of the Company’s shares;
	o	Beyond issuing the shares noted above, the Company shall not take any additional action that would cause the note holder to incur tax consequence from the transfer or would affect the note holder’s tax consequences in any way.

The Company issued the 4,000,000 shares of common stock on June 20, 3018. At June 30, 2018, the Company had no indebtedness to this holder of the note payable principal or accrued interest.

In January 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $110,000. The note, which is due on October 12, 2018 has an original issue discount of $10,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.20 or (ii) 65% of the lowest per share trading price for the fifteen (15) trading days immediately following the 180^th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $4,099.

In January 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $91,300. The note, which is due on October 30, 2018 has an original issue discount of $8,300. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of 5,073.

In February 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $63,800. The note, which is due on November 30, 2018 has an original issue discount of $5,800. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,853.

In March 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $77,000. The note, which is due on December 5, 2018 has an original issue discount of $7,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $.0.06 or (ii) 75% of the average of the three daily VWAPs for the trading price for the twenty (20) trading days before the 181^stcalendar date of the note or the ten (10) trading days if after the 181st calendar day of the note. During the six months ended June 30, 2018, the Company recognized interest expense of $1,975. As of June 30, 2018, the institutional investor exercised its MFN provision in Paragraph 4a increasing the OID from the stated in the note from 10% to 15% thus increasing the amount owed to $80,500.

In March 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $72,450. The note, which is due on December 30, 2018 has an original issue discount of $9,450. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days immediately following the 180^thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,453.

Critical Accounting Policies

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2017, for disclosures regarding the Company’s critical accounting policies and estimates, as well as any updates further disclosed in our interim financial statements as described in this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company”, we are not required to provide the information under Item 3.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of disclosure controls and procedures.

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2018, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the six months ended June 30, 2018, the Company issued 2,550,000 shares of common stock for marketing and consulting services valued at $235,900.

ITEM 2. EXHIBITS.

(a)

The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.		Description

31.1		Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

eWellness Healthcare Corporation
(Registrant)

By:	/s/ Darwin Fogt	Date: August 14, 2018
	Darwin Fogt
	President, CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Darwin Fogt	Chief Executive Officer and Director	August 14, 2018
Darin Fogt	(principal executive officer)

/s/ David Markowski	Chief Financial Officer	August 14, 2018
David Markowski	(Principal Financial and Accounting Officer)

/s/ Brandon Rowberry	Director	August 14, 2018
Brandon Rowberry

/s/ Douglas Cole	Director	August 14, 2018
Douglas Cole

/s/ Curtis Hollister	Director	August 14, 2018
Curtis Hollister

/s/ Douglas MacLellan	Director	August 14, 2018
Douglas MacLellan

/s/ Rochelle Pleskow	Director	August 14, 2018
Rochelle Pleskow

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Darwin Fogt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018 of eWellness Healthcare Corporation (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2018

/s/ Darwin Fogt
Darwin Fogt,
Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David Markowski, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018 of eWellness Healthcare Corporation (the “registrant”);

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2018

/s/ David Markowski
David Markowski,
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2018 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Darwin Fogt, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	eWellness Healthcare Corporation.

Date: August 14, 2018	By:	/s/ Darwin Fogt
		Darwin Fogt, Director and Chief Executive Officer
		(Principal Executive Officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2018 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	eWellness Healthcare Corporation

Date: August 14, 2018	/s/ David Markowski
	David Markowski, Chief Financial Officer
	(Principal Financial and Accounting Officer)

GRAPHIC 6 img_001.jpg begin 644 img_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WXG%&X4C8 MXSTK+O[_ !^YAY8\$USXC$1H1YI,"]->10(68DX[+C-4AK]H7"[)]:^C:]%? PSMLE!X![UZD%+EU,HUM>62LS?WCWJI=: MK;6:,TC$[>H4C/\ .L?Q%K$]B(XK>-R7'+ 9Q6!;Z'J&I%KFZE,<9(P&./QK M:$$]V$ZCORQW-X^.=+$WE^3=9SC.UYN3\U9=WH6J:/-]HM6>6$<_*V:T]G3EI'<<9S^T>F;J,US'AOQ(M]%] MGN6"W"G&UNM=,#FN>47%V9JG<=1112&%%%% !11FB@ HHHS0 4444 %%%% ! M11FDS0 M%&:,T %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*** "B MBC- !1110 4444 %%%% !29HS1Q2N M)FC(HSS0P%HHHI@%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110!3U&X6"W.3R0<5DZ8@WR3S#( SFIO$0) M%O@X'S9/Y5#9L'TB98N2!7DU:;J8Q-K1?Y$.=M"I>7=QJ%RUO Q,?MVJM-X; MN0FZ&=B_7!-/\+RA-0G23 Z5J0GD?,+MP?:O2H4NIR3FG#FD1Z= MJDME,;34%.P_+EJ36M,V.E_I_*XR?+YK1N$M_$FG[X"!.@R/6L33=2FT*\-G M=@B)CSGH*[8)[H.1>J-;0]8M]0407H431_=)J#Q.VIRWR6MHC?9RGWE'>JWB M#1A<1KJ6F9R>?EJUX7\0^;$UG>D+,O"EJ;C]M?<:QC9>+AM^, M[=U7_#^N2P7']F:BW/3YASS6U%::DFNF5IMUL1Q]*Y/Q/(ESXJ5+4YP5W%:2 MESWN;*-A?$]L='\0QW5N<*^#A:] TNZ^UZ;#,/XEY^MSQ1FFX&.E0SW$5NA:1@*Y)245=["+&:3.:Y^;Q M+!&S#RR0.^:LV>M07+8"[3[USK&4I.R8KHAU?Q-;Z3*(I$;=]*T--U.+4X!+ M%TQ7)^.K7S DR#GKFI? 5P7BEB)^Z*ZQG2:IJ\.EQAY>XQ65X&M2UQ+=.-J@<$T >@B@]*PKOQ186CD-(&&>U+:>)K* MZ95W 9..30!>U>=K73+B9!ED3(KAM)\4ZC8Z !_;%OSC]YR>U 'H7BC4)].TLRP-M?BL7POX@O-1U,0W#[EQ5_P ;\Z$" M#D9%(+.Q0,7WY["@#8HK M%T_Q%::A)L4[#CN:UMP W$C;0!)16-?^(K*Q;:9 S#J,U#9^*K"\EV!@ON3U MH WZ*8KAE#*05/<5G:AK=GIX'F2 MZ"@#4HKFHO&%C*^T@#97"+FFP2B5=U-N?\ 4'-1 MV7RQMD8YJ.9\P%S-%59KM83CJ?05"-0Y^9"!0ZB6@&AFC-11NKKE3UJ":\CC M..I]*IS25P+F::QP,U26_4X!0BK:N'3(Z4E4BP((IP\K+SP:EFE$41)/2J=N M2;J3D$9I+R[ 5HPA],FLG.T6P+L3F2%6'>H9+DI,$'/-16EWYD2 (0.E$Y_T MI"W '%/G]U- : /%+FJ4EVB,0!N/M2PWDH%_-%1JX9<@C%1/=1J"J/#<9\M^.>@KM74$@XZ5C:WH\5_#D#$H.0:2@G M-,PJP;5UT,?7=.VM'J%DQQWV]JDTC4X=3B-C?!&DQPW7-9VG:I-H]XUK>@^2 M3@9YJQKFDI+$-1TTA3G)VUTJ*M9[&%KRYE\T4+^UNO#5X+B!SY3GL>,5ME;/ MQ3I9D1$^T*,9[@U3T'6$U".33M2"[L?*S?\ UZS=7T^Y\/7RW=F6\D\G:>*O M5O727X&D8JUEL)9:E=>&;][:Y#M Q[G(K2UW1X]3MEU+2@ ^,DIQBK5I-8^* M].*3!1<(,5@12ZCX1O6W9:TSDC&Y\6:X&162 $*"#7I.GVBV5C%;YSM&,TVQTVVT^(1P1*H[D"KG%8 MU9\RY5L#:&NP52?2N+O[N2XN)"YPN[:.:ZG4P39.%!Z5Q\4:":-YF C)P>.: M\+,IR=J:=D939M6B:8MFC2*C2$('<.>G. M*FMK"P=OW6&VGI4.A*IRJ+6@G%,IZO ;CPP2PRP3(KE?!EV8-08$[<]<]Z]$ MN;<263Q8XVXQ7C\\LEAJ,OE\%6(KVZ<>6*1HC0U#=J7BEH6SM+G'YU$+=M+\ M0I$ 0 _7\:U/!]M]OU8SOU4Y)J?QQ;BVNTN$&"W>K&)XSNUNO)QR%[56EOFT M_0XEB)#N,''%8D5Q+?W,,;GJP&:V_$EL;:"%,$4 0^'M$7590\\P"CJ#WH\0 MZ(NDSAXI1M)X(/2F:+I%Y>1,8)V0?[)K1E\'ZE.^9)2P'3)H OZ9J+W7A6YB MD8LRQD#- 'Z5UD&A3:1H]WO)8&,G&:Y3073]06,,0RM MP17;ZUJTD/AE-K$2L ,YKE-;.[6B/>M+Q!&YTF#!^7 YI@4/#^C_ -L7C>=, M=J_,Q;^56_$>@Q::$EMY 03C [5G:%IEYJ,LBV\I1AZ'%;#^$=2F $UQ(<$D M9- $WAG5)UTJ[B:1F*CY3FN?B3[9K*I=RG8S'))Z5V?A_0CI3RRW3 JPP=U5 M=5\+VFH3&:QN%#L3D"D M_X4LI; 26#*9!Z=ZC\.:9J6G:AM9"L;$<=JPKNR MUG1LLDD@B4D 7?AB]M;LM:! MC&&RK"NK5I8K&W^T$^8!WKB;/Q!J>EW8CN6? /*FNZBNUU&VM;@ ;7'-957[ M@%Q+X8&$)XI?MQ[H:LI$A0'8#Q2B&,=$%)1DTM16*,UYF(Y6D2?R[$N1@DU: MN8T$)^4?E5"5=]A@GO64N:+W%J6;2.+'FL0S-ZU8<0NI!52/I56"S!B4[CTJ M3[%R,,<52YN78:((B$+QQOP3Q5J"U2,9;YF]32"&&U5I#V[U61)[HEQ(R*3Q MBA7CJP+[(C@@@'\*J665FE3/ /%*+)\@>:WUJ.PB,4\@+;O>B4G?88^V'^E2 M>N>:EO8T-NV5%0VQ_P!+<58O/^/9J%9P8"VJ*($P!TK/U%6DNHXP?E) K0M? M^/>/Z55G_P"/Q1GC-$E>"L(N10K&N-H^M5KV!=H<<,#Q5X8Q5>\.V.KE%*(R M">5C;H%_BXJQ!;)$F !]:IRC"1G/!88]JT0"![=ZFFKO45B&YMU>%_E!;'%0 M0QS&VV$G!JOIMN7G>1_F7L#4ME%Y:2C.3SSFIM//#5F MH\[7-T$B>X=(("0, \<56M8D"F1VW,W3-2:D-UN1ZD5%#9CRURY%5*[G9!-/BLTB;=U/O3<92>PR*2Q$C'!Q3K"R^R-* M2<[\?IG_ !JY0*M4XIIV%9"T445J,1J:0#UIYI,4O,6YC:SH<&I0_="S+R& MYKD;34+OP_?-;W>Y[=^,/R*]&(K)UK0[?5[8JZ?O!]ULUM3J+X9&MT<_K M6BV][:IJ.E824C2%5<994[U((-7M%)' W M+UHL)/$.FM]G>-9HAR"PY%=':0)=J9;FV59![5$IV5GJ:)$=GI.EL!-!:JGL M!BM1$"*%7@#M0D:1C:@P*=BN>5WL,,>].HHI"(W0."",UB7?A])9&DB(0L:W ML4 8%95,/3J+WD)I,YD>'Y3PTK8'O6KI^FQV*84DD]:OEE*\:R)M<;A[TP/(M'TV635K<;&"+(-U>@^)-$& MJ6'[L8EC&4Q6M%86L+;HX5!]<58P/2@#R*VN]2T&?]WYBXZCM6@_B_5KI=D0 M*L?0=Z]$FTZTN#F6!'/N*CCT>PB(*6L:L.X% &/&][<>$YQ>!O-*$?6N)T2V MF76+;,9P'[UZP8PRE&4%>F*@BT^VC8,L*AO7% &#XT1I-%"*,^H%%6;UQ4RQJB[4&T>U 'DD9U/P_=;UWQG.#QUK0;Q?JMP MOE1[MWJ*]%GL;:Z_UT*O]142:18QOE;6,>X% &#HXU'5=)GBOBP?^$FN7G75 M= OMP,A53QSU%>HJ@0!5&%]*CFM(+@8FB5Q[B@#S2_\ %=[JMJ;0Q$%NIQ5_ MP?HB'<:@T\2B:1G!&\GK5]+:)/NJ!3]@![5+IR M;NV!1M@1>/Q5BZ4O;L%ZU,(P"2 ,FG8R,52A9- 4+.[C\I(V/S#BFS FY4@Y M&:M?8X=VX+S4NP<<](R[A@CBK<;JPF46@\RV!& M: MNQVL49RJ 'UJ4C(I>S;U; H07R%<,0K>E)/>!XV2+.[%6FM86.2@S3E@C3[J M@4N2>UP,S3TD02"0D\=ZLZ>N _&.:N; #FE"XZ=*(TVK7 CN(A+&5-4(IWMI M"DY.WL:T\&F20+(,,H(JI0DW=,3(&OH@N0<_A3[:9IMQ. .U LX5QA#^=3+& MJ<*,41C.^K&. I:3&*6M0"BBB@ HHHH 0]*0]*** ,'Q/:07%@&EB5B.A-<+ MHEQ-9W)6WE9%;J >O-%%;Q^$$>DZ=*\L0,C;CCN*O #I1164MQRW%[TZBBI M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D! end EX-101.INS 7 ewll-20180630.xml XBRL INSTANCE FILE 0001550020 2017-01-01 2017-12-31 0001550020 2017-12-31 0001550020 2016-12-31 0001550020 EWLL:EscrowTrustMember 2018-06-30 0001550020 srt:MinimumMember 2018-01-01 2018-06-30 0001550020 srt:MaximumMember 2018-01-01 2018-06-30 0001550020 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001550020 srt:MinimumMember 2018-06-30 0001550020 srt:MaximumMember 2018-06-30 0001550020 EWLL:OfficersMember 2017-12-31 0001550020 EWLL:OfficersMember 2018-06-30 0001550020 us-gaap:WarrantMember 2017-12-31 0001550020 EWLL:FormerSecretaryTreasurerandCFOMember 2018-06-30 0001550020 EWLL:NonConvertibleNotePayableMember 2017-02-28 0001550020 EWLL:NonConvertibleNotePayableMember 2017-02-01 2017-02-28 0001550020 EWLL:NoteHolderMember 2017-02-28 0001550020 EWLL:NoteHolderMember 2018-06-30 0001550020 EWLL:NoteHolderMember 2017-01-01 2017-06-30 0001550020 EWLL:NoteHolderMember 2018-01-01 2018-06-30 0001550020 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001550020 2017-06-30 0001550020 EWLL:ConvertibleNoteMember EWLL:WarrantOneMember 2017-04-01 2017-04-30 0001550020 EWLL:ConsultingAndMarketingServicesMember 2018-01-01 2018-06-30 0001550020 EWLL:ConvertibleNoteMember us-gaap:WarrantMember 2017-02-01 2017-02-28 0001550020 EWLL:ProgrammingCompanyMember 2018-06-30 0001550020 2018-01-01 2018-06-30 0001550020 2018-06-30 0001550020 2017-01-01 2017-06-30 0001550020 us-gaap:FairValueInputsLevel1Member 2018-06-30 0001550020 us-gaap:FairValueInputsLevel2Member 2018-06-30 0001550020 us-gaap:FairValueInputsLevel3Member 2018-06-30 0001550020 EWLL:ProgrammingCompanyMember 2017-04-01 2017-04-02 0001550020 EWLL:ProgrammingCompanyMember 2017-04-02 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember 2018-01-31 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember 2018-01-01 2018-01-31 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember 2018-01-01 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMember 2018-01-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMember 2018-01-01 2018-01-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMember 2018-01-01 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberOneMember 2018-02-28 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberOneMember 2018-02-01 2018-02-28 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberOneMember 2018-01-01 2018-06-30 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteOneMember 2018-03-31 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteOneMember 2018-03-01 2018-03-31 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteOneMember 2018-01-01 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberTwoMember 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberTwoMember 2018-06-01 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberTwoMember 2018-01-01 2018-06-30 0001550020 EWLL:BoardOfDirectorsMember EWLL:AdvisoryAgreementMember 2018-01-01 2018-01-31 0001550020 us-gaap:CommonStockMember 2018-06-30 0001550020 EWLL:EquityIncentivePlanMember EWLL:BoardOfDirectorsMember 2018-01-01 2018-01-31 0001550020 EWLL:EquityIncentivePlanMember EWLL:OfficersDirectorsAndConsultantsMember 2018-01-01 2018-01-31 0001550020 EWLL:BoardOfDirectorsMember 2018-06-30 0001550020 EWLL:BoardOfDirectorsMember 2018-06-01 2018-06-30 0001550020 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001550020 EWLL:WarrantOneMember 2018-01-01 2018-06-30 0001550020 us-gaap:WarrantMember 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember 2018-06-30 0001550020 EWLL:ProgrammingCompanyMember 2016-11-30 0001550020 EWLL:EquityIncentivePlanMember EWLL:OfficersDirectorsAndConsultantsMember 2018-03-01 2018-03-30 0001550020 2018-04-01 2018-06-30 0001550020 2017-04-01 2017-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExercisePriceMember 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExercisePriceMember 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputPriceVolatilityMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputPriceVolatilityMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-01-01 2018-06-30 0001550020 EWLL:ProgrammingCompanyMember 2016-11-28 2016-11-30 0001550020 EWLL:CommonStockOneMember 2018-06-19 2018-06-20 0001550020 EWLL:CommonStockTwoMember 2018-06-19 2018-06-20 0001550020 2018-06-19 2018-06-20 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember us-gaap:InvestorMember srt:MinimumMember 2018-01-01 2018-06-30 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember us-gaap:InvestorMember srt:MaximumMember 2018-01-01 2018-06-30 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember srt:MaximumMember 2018-06-30 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember 2018-05-01 2018-05-30 0001550020 EWLL:EightPercentageFixedConvertiblePromissoryNoteMember 2018-05-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMember 2018-05-01 2018-05-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMember 2018-05-30 0001550020 EWLL:UnitedStatesFederalDistrictCountMember 2018-01-01 2018-06-30 0001550020 EWLL:UnitedStatesFederalDistrictCountMember 2018-06-30 0001550020 EWLL:ConsultingAgreementMember 2018-06-01 2018-06-30 0001550020 EWLL:ConsultingAgreementMember EWLL:JulyTwoThousandandEighteenMember 2018-06-01 2018-06-30 0001550020 EWLL:ConsultingAgreementMember us-gaap:CommonStockMember 2018-06-01 2018-06-30 0001550020 EWLL:EquityPurchaseAgreementMember us-gaap:InvestorMember srt:MaximumMember 2018-06-01 2018-06-30 0001550020 EWLL:EquityPurchaseAgreementMember us-gaap:InvestorMember srt:MaximumMember 2018-06-30 0001550020 EWLL:EquityPurchaseAgreementMember us-gaap:InvestorMember 2018-06-01 2018-06-30 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberTwoMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberTwoMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberOneMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteMemberOneMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:ThreePercentFixedConvertiblePromissoryNoteMemberMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 2018-08-13 0001550020 us-gaap:SubsequentEventMember EWLL:ConsultingServicesAgreementMember 2018-07-01 2018-07-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteTwoMember us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001550020 EWLL:TwelvePercentFixedConvertiblePromissoryNoteTwoMember us-gaap:SubsequentEventMember 2018-07-31 0001550020 us-gaap:SubsequentEventMember 2018-07-31 0001550020 us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure EWLL:Integer

.001

0.001

The following is a summary of the status of the Company’s warrants as of June 30, 2018 and changes during the six months ended on that date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life (yrs.)</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">8,753,179</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.21</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">2.4</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.038</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">417,429</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.0</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,217,429</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1.0</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">5,953,179</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.31</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.4</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.038</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">5,953,179</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.31</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.4</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.038</td> <td style="line-height: 107%"> </td></tr> </table>

20000000

0.001

.001

400000000

The assumptions used in the Black Scholes valuation of the date of issuance are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 107%">Stock price on the valuation date</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">.0673-.089</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price of warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.004 and .25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.00</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Years to maturity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3-4</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk free rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.33%-2.68</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">245.23%-257.73</td> <td style="line-height: 107%">%</td></tr> </table>

13654354

569998

3220392

4000000

The following is a summary of the status of all Company’s stock options as of June 30, 2018 and changes during the six months ended on that date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Stock</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life (yrs)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">20,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.26</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1.9</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">20,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.26</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.8</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">16,398,958</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.8</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Note 1. The Company   The Company and Nature of Business   eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated no revenues to date.   eWellness is the first physical therapy telehealth company to offer insurance reimbursable real-time distance monitored treatments. Our business model is to license our PHZIO (“PHZIO”) platform to any physical therapy (“PT”) clinic in the U.S. and or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program. The Company’s PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries. PHZIO re-defines the way physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as: Anthem Blue Cross and Blue Shield.

Note 2. Summary of Significant Accounting Policies   Basis of Presentation   The accompanying condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2018. The unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.   Going Concern   For the six months ended June 30, 2018, the Company had no revenues. The Company has an accumulated loss of $18,557,051. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.   Fair Value of Financial Instruments   As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td></tr> </table>   As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td></tr> </table>

Note 3. Related Party Transactions   During the six months ended June 30, 2018, a company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, invoiced the Company $10,430 for accounting services. The amount outstanding as of June 30, 2018 and December 31, 2017 was $1,920 and $700, respectively.   In April 2015, the Company entered into an operating agreement with a physical therapy company (“EPT”) which is owned by the Company’s President and Chief Executive Officer. Through the agreement, the Company agrees to provide operating capital advances for EPT to offer the Company’s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPT shall be allocated monthly. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.   In November 2016, the Company signed an agreement with a programming company (“PC”) within which one of the Company’s directors and Chief Technical Officer is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHIZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company’s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHIZIO platform. The agreement establishes that the Company is indebted to the PC for $225,000 for past programming services. For this amount, the Company issued 25,280,899 common shares at a value of $0.0089 per share on April 1, 2017. The PC will also have the right to appoint 40% of the directors. At the end of June 30, 2018, the Company had a payable of $562,832 due to this company.   The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Statement of Operations and Additional Paid in Capital in the Balance Sheet.   Throughout the period ended June 30, 2018, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2018 and December 31, 2017 were $0 and $5,828, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $218,000 and $205,000 at June 30, 2018 and December 31, 2017, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $1,120,960 and $1,071,369 at June 30, 2018 and December 31, 2017 respectively.

Note 4. Non-Convertible Notes Payable   In February 2017, the Company was served by a complaint filed by the holder of a note payable. The action was removed from Louisiana state court to the United States Federal District Court in Baton Rouge, LA. The lawsuit alleges that the Company is indebted to the note holder a promissory note stemming from four loans to the Company during the 20 months prior to February 2017 amounting to $75,500 in total original principal bearing interest at 12% per annum, of which $45,202 has been repaid. Further, the note holder claims that, because of alleged defaults and extensions of the notes, the Company is now indebted in the amount of $253,877 inclusive of interest and penalties at an effective rate exceeding 70% per annum, far more than the maximum rate allowable in California or Louisiana. The Company and its counsel have determined that: (i) the note holder is not a licensed lender in the State of California, where the loan was made and the $75,500 was deposited and therefore was not permitted under California law to make loans in the State; and (ii) the interest rate the note holder is seeking to collect is usurious and therefore interest claimed in the lawsuit is neither collectible nor enforceable. In October 2017 the complainant and his counsel motioned to dismiss the unlicensed lender assertion. In January 2018 the U.S. District Court, Louisiana ruled that the unlicensed lender assertion was to proceed. The Company and counsel believe that the suit is wholly without merit and the company will prevail.   On June 20, 2018, a settlement agreement was signed between the Company and holder of the note payable with the following terms for the cancellation of the note payable, accrued interest and warrants:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">1.</td> <td style="text-align: justify; line-height: 107%">The Company will issue 2,709,444 shares of commons stock that is immediately tradeable under Securities and Exchange Commission Rule 144, but subject to a daily trading limit of 25,000 shares per day;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">2.</td> <td style="text-align: justify; line-height: 107%">The Company will issue 1,290,556 shares of common stock that shall be subject to a 180-day holding period and are also subject to a daily trading limit of 25,000 shares per day;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">3.</td> <td style="text-align: justify; line-height: 107%">The holder of the note payable shall bear all fees and expenses, including attorneys’ fees, associated with the transfer and trading of the Company’s shares;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">4.</td> <td style="text-align: justify; line-height: 107%">Beyond issuing the shares noted above, the Company shall not take any additional action that would cause the note holder to incur tax consequence from the transfer or would affect the note holder’s tax consequences in any way.</td></tr> </table>   The Company issued the 4,000,000 shares of common stock on June 20, 3018. At June 30, 2018, the Company had no indebtedness to this holder of the note payable principal or accrued interest. During the six months ended June 30, 2018 and 2017, the Company accrued interest expense totaling $15,183 and $16,071, respectively.

Note 5. Convertible Notes Payable   In January 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $110,000. The note, which is due on October 12, 2018 has an original issue discount of $10,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.20 or (ii) 65% of the lowest per share trading price for the fifteen (15) trading days prior to the conversion date. Conversion into shares of common stock can commend immediately following the 180th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $4,099.    In January 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $91,300. The note, which is due on October 30, 2018, has an original issue discount of $8,300. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock can commence immediately following the 180th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $5,073.   In February 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $63,800. The note, which is due on November 30, 2018, has an original issue discount of $5,800. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock can commence immediately following the 180th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,853.   In March 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $77,000. The note, which is due on December 5, 2018, has an original issue discount of $7,000. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the average of the three daily VWAPs for the trading price for the twenty (20) trading days before the 181st calendar date of the note or the ten (10) trading days if after the 181st calendar day of the note. During the six months ended June 30, 2018, the Company recognized interest expense of $1,975. As of June 30, 2018, the institutional investor exercised its MFN provision in Paragraph 4a increasing the OID from the stated in the note from 10% to 15% thus increasing the amount owed to $80,500.   In March 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $72,450. The note, which is due on December 30, 2018, has an original issue discount of $9,450. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to the conversion date. Conversion into shares of common stock immediately following the 180th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $2,453.   In May 2018, the Company executed an 8% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $125,000. The note, which is due on May 10, 2019, has an original issue discount of $3,750. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock at a price equal to 72% of the lowest VWAP for the ten (10) trading days prior to and including the conversion date. Conversion into shares of common stock can commence following the 180th calendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $1,370.   In May 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $51,750. The note, which is due on March 1, 2019, has an original issue discount of $6,750. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) the fixed conversion price of $0.20 or (ii) 75% of the VWAP for the trading price for the ten (10) trading days prior to and including the conversion date. Conversion into shares of common stock can commence following the 180thcalendar day after the Original Issue Date. During the six months ended June 30, 2018, the Company recognized interest expense of $612.

Note 6. Equity Transactions   Common Stock   In January 2018, the Board of Directors approved the extension of an Advisory Agreement dated February 15, 2015 for one year. The Company issued 800,000 shares of common stock as compensation with a value of $104,000. This value is being amortized over the life of the contract.   During the six months ended June 30, 2018, the Company agreed to issue a total of 200,000 shares of common stock for consulting services at a value of $14,800. At the end of June 30, 2018, these shares had not yet been issued and are recorded in Shares to be Issued.   During the six months ended June 30, 2018, the Company issued a total of 13,654,354 shares of common stock per debt conversion of convertible notes dated April, July, September and December 2017. The total of the debt conversion was $569,998 which includes $19,776 of accrued interest.   During the six months ended June 30, 2018, the Company issued 2,550,000 shares of common stock for marketing and consulting services valued at $235,900.   During the six months ended June 30, 2018, the Company issued 4,000,000 shares of common stock for settlement of a complaint filed in the United States Federal District Count (see Footnote 4). The debt settled totaled $236,868 which includes $56,817 of accrued interest.   In June 2018, the Company entered into a consulting agreement within which the Company agreed to issue 125,000 shares of common stock per month beginning in July 2018 and 1,500,000 shares of common stock upon signing of the agreement. The 1,500,000 shares of common stock were issued with a value of $105,000 which is being amortized over the life of the contract.   In June 2018, the Company executed an Equity Purchase Agreement with an institutional investor within which the investor agrees to purchase up to $1,500,000 of the Company’s common stock, par value $0.001. As an inducement to the investor to enter into the agreement, the Company issued 1,000,000 restricted shares of common stock to the investor valued at $70,000.   In January 2018, the Board of Directors agreed to form an eWellness Healthcare Corporation 2018 Equity Incentive Plan (“Plan”). The Plan shall be for 20,000,000 shares of common stock that will be placed in a 10b5-1 Sales Plan that will be registered under an S-8 Registration Statement. Under the sales plan, each recipient will open an account with Garden State Securities (“GSS”) for management of all sales of shares issued under the Plan. Quarterly limitations are placed on the number of shares that can be sold. The Company initially allocated 17,400,000 shares to officers, directors and consultants. As of June 30, 2018, no shares have been issued.   Stock Options   The following is a summary of the status of all Company’s stock options as of June 30, 2018 and changes during the six months ended on that date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Stock</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life (yrs)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">20,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.26</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1.9</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">20,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.26</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.8</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Options exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">16,398,958</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.8</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   The Company recognized stock option expense of $217,188 and $217,288 for the six months ended June 30, 2018 and 2017.   Warrants   In March 2018, the Board of Directors, at the request and with the approval of the investors, determined that it was in the best interests of the Company and the Investors, based upon market price and relatively limited liquidity of the shares of common stock that the Company revised the expiration date and exercise price for 417,429 unexercised warrants granted on April 9, 2015. The original expiration date of April 9, 2018 is extended to April 9, 2019. The original exercise price of $.35 is reduced to $.05.   In February 2017, the Company authorized the issuance of 68,750 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $5,932.   In April 2017, the Company authorized the issuance of 1,232,000 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $106,732.   The following is a summary of the status of the Company’s warrants as of June 30, 2018 and changes during the six months ended on that date:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life (yrs.)</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">8,753,179</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.21</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">2.4</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.038</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">417,429</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.0</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,217,429</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">0.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1.0</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">5,953,179</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.31</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.4</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.038</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">5,953,179</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.31</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.4</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.038</td> <td style="line-height: 107%"> </td></tr> </table>   For purpose of determining the fair market value of the warrants and options outstanding at June 30, 2018, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessarily as of the reporting date. The assumptions used in the Black Scholes valuation of the date of issuance are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 107%">Stock price on the valuation date</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">.0673-.089</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price of warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.004 and .25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.00</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Years to maturity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3-4</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk free rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.33%-2.68</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">245.23%-257.73</td> <td style="line-height: 107%">%</td></tr> </table>

Note 7. Commitments, Contingencies   The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.   The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”).   Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.   Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.   However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.    As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419 but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.   Because of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. Because of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.   Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining currently the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. Considering the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.   From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Note 9. Subsequent Events   In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 17, 2019 has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note.   In July 2018, the Company executed an 3% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $180,000 for funding in three tranches. The note, which is due twelve months from the date of each individual tranche, has an original issue discount of $10,000 per tranche. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to 75% of the market price which is lowest trading price during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The trading price is the lesser of: (i) lowest traded price or (ii) the lowest closing bid price on the OTCQB. The first tranche of $60,000 was received in the month of July.   In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $28,250. The note, which is due on April 17, 2019 has an original issue discount of $3,250. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note. The Company issued 50,000 shares of common stock valued at $4,000 upon the execution of this note.   In July 2018, the Company entered into a consulting services agreement with a consultant for one year for a monthly fee of $5,000.   In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 30, 2019 has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average VWAP for the ten(10) trading day period ending on the latest compete trading day prior to the conversion date. The Company issued 100,000 shares of common stock valued at $8,000 upon execution of this note.   During the month of July to the filling of this report, the Company has issued 700,000 shares of common stock for consulting services valued at $52,775.   During the month of July to the filing of this report, the Company issued 7,408,058 shares of common stock for conversion of convertible debt valued at $369,843 which includes $138,983 of accrued interest and default fees.

Basis of Presentation   The accompanying condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2018. The unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

Going Concern   For the six months ended June 30, 2018, the Company had no revenues. The Company has an accumulated loss of $18,557,051. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instruments   As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td></tr> </table>   As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td></tr> </table>

As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">376,951</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td></tr> </table>   As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify; line-height: 107%">Derivative Liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total Liabilities measured at fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,140,578</td> <td style="line-height: 107%"> </td></tr> </table>

During the six months ended June 30, 2018, the Company had the following activity in the derivative liability account:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify; line-height: 107%">Derivative liability at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Addition of new conversion option derivatives</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">91,283</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Extinguishment due to note conversions</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(258,823</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Extinguishment due to note cancellations</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(202,610</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Changes in fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(393,477</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Derivative liability at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td></tr> </table>

The significant assumptions used in the Black Scholes valuation of the derivative are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 107%">Stock price at valuation date</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">.0725-.089</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price of warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.004 - .25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Conversion rate of convertible debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.0495 – 0.2000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Risk free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.93%-2.68</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock volatility factor</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">110.9%-257.73</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Years to Maturity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">.08 – 4</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> </table>

1140578

376951

1140578

376951

10430

700

1920

5828

562832

0.12

0.75 0.40

200000

2550000

25280899

700000

205000

218000

1071369

1120960

75500

The Company is indebted to the note holder a promissory note stemming from four loans to the Company during the last 20 months amounting to $75,500 in total original principal bearing interest at 12% per annum

45202

75500

253877

0.70

16071

15183

4099

5073

2853

1975

2453

1370

612

110000

91300

63800

77000

72450

80500

125000

51750

56500

28250

180000

56500

0.20

0.0495

0.2000

0.20

0.21

0.20

2018-10-12

2018-10-30

2018-11-30

2018-12-05

2018-12-30

2019-05-10

2019-03-01

2019-04-17

2019-04-30

20000000

17400000

2709444

1290556

4000000

125000

1500000

50000

100000

1232000 68750

.004

.25

0.35

10000 8300 5800 7000 9450 3750 6750 6500 3250 10000 10000 10000 6500

0.65

0.75

0.72

0.75

569998

569999

3220392

236868

14800

235900

52775

20000000

800000

16398958

0.26

0.28

P1Y10M25D

P1Y9M18D

8753179

5953179

417429

3217429

5953179 0.21 0.31 0.05 0.05 0.31 P2Y4M24D P1Y P2Y4M24D P2Y4M24D 0.038 0.038 0.038

0.0673

0.089

0.725

0.89

0.0000

P3Y

P4Y

0.0233

0.0268

2.4523

2.5773

5932

106732

142352406

165856760

142352406

165856760

104000

417429 The original expiration date of April 9, 2018 is extended to April 9, 2019. .05 eWELLNESS HEALTHCARE Corp 0001550020 10-Q 2018-06-30 false --12-31 Smaller Reporting Company EWLL Q2 2018

-0.01

0.03

-0.01

-0.02

The Company's PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries.

500

0.0089

174114818 0.10

90000

0.90 0.10 0.90

100000

10000 90000

1140578

376951

91283 -258823

-393477

Note 8. Derivative Valuation   The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favored Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.   The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2018 and 2017, the Company amortized the debt discount of $239,710 and $82,443, respectively. The derivative liability is adjusted periodically according to stock price fluctuations and other inputs and was $376,951 and $1,140,578 at June 30, 2018 and December 31, 2017, respectively.   During the six months ended June 30, 2018, the Company had the following activity in the derivative liability account:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify; line-height: 107%">Derivative liability at December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">1,140,578</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Addition of new conversion option derivatives</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">91,283</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Extinguishment due to note conversions</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(258,823</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Extinguishment due to note cancellations</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(202,610</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Changes in fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(393,477</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Derivative liability at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">376,951</td> <td style="line-height: 107%"> </td></tr> </table>   For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 107%">Stock price at valuation date</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">.0725-.089</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price of warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.004 - .25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Conversion rate of convertible debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">.0495 – 0.2000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Risk free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.93%-2.68</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock volatility factor</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">110.9%-257.73</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Years to Maturity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">.08 – 4</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> </table>

19776

56817

138983

217188

P1Y 0.004 0.25 0.0193 0.0268 1.109 2.5773 0.00 P29D P4Y

179827

171570

186709

180653

5021

8439

13954

12477

205684

201569

345956

316025

351511

564752

210828 218000

1071369

1120960

90000

444680

669650

1140578

376951

180051

3834973

3356338

3834973

3356338

142352

165857

13178131

15221625

-16949772

-18557051

-3629289

-3154769

205684

201569

14800

204000

102000

487438

418178

290748

234841

952851

1316732

440326

612721

5000

1644289

1938910

833074

949562

-1644289

-1938910

-833074

-949562

8091

37404

692

24691

393477

4399596

-116275

-843038

319800

223920

139891

120567

-1605652

2274170

-1131679

-1888476

1627

800

1627

-1607279

2273370

-1133306

-1888476

-43131

-0.01

0.03

-0.01

-0.02

151077846

82876801

156216150

105459623

151077846

85564942

156216150

105459623

2996

2512

111000 109500 250700 94150

217188

239710

176296

126992 789994

-8091

393477

4399596

-90265

43752

38572

22583

213241

17169

7172 77441

49591

47666

-532107

-615479

4937

2910

-4937

-2910

594800

776500

1005

54550

110550

539245

665950

2201

47561

6882

13995

61556

9083

1267

800

209000 278500 109978 309000

100000

50000 225000

25000

0.10 0.15

105000

4000

8000

1000000

70000

-202610

60000

70000 86730 219526 155885

7408058

369843

EX-101.SCH 8 ewll-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Non-Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments, Contingencies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Derivative Valuation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Derivative Valuation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Non-Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity Transactions - Schedule of Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Commitments, Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Derivative Valuation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Derivative Valuation - Schedule of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 ewll-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 ewll-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 11 ewll-20180630_lab.xml XBRL LABEL FILE Related Party Transactions By Related Party [Axis] Escrow Trust [Member] Range [Axis] Minimum [Member] Maximum [Member] Fair Value, Hierarchy [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Title of Individual [Axis] Officers [Member] Equity Components [Axis] Warrant [Member] Former Secretary-Treasurer and CFO [Member] Debt Instrument [Axis] Non-Convertible Notes Payable [Member] Note Holder [Member] Class of Stock [Axis] Common Shares [Member] Convertible Note [Member] Warrant One [Member] Income Statement Location [Axis] Consulting and Marketing Services [Member] Programming Company [Member] 8% Fixed Convertible Promissory Note [Member] 12% Fixed Convertible Promissory Note [Member] 12% Fixed Convertible Promissory Note One [Member] 8% Fixed Convertible Promissory Note One [Member] 12% Fixed Convertible Promissory Note Two [Member] Board of Directors [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Advisory Agreement [Member] Plan Name [Axis] Equity Incentive Plan [Member] Officers, Directors and Consultants [Member] Award Type [Axis] Derivative Liability [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Measurement Input Type [Axis] Measurement Input, Exercise Price [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Measurement Input, Expected Dividend Rate [Member] Common Stock One [Member] Common Stock Two [Member] Investor [Member] Geographical [Axis] United States Federal District Count [Member] Consulting Agreement [Member] Award Date [Axis] July 2018 [Member] Equity Purchase Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] 3% Fixed Convertible Promissory Note [Member] Vesting [Axis] Tranche One [Member] Tranche Two [Member] Tranche Three [Member] Consulting Services Agreement [Member] 12% Fixed Convertible Promissory Note Two [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid Expenses Total current assets Property & equipment, net Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Contingent liability Convertible debt, net of discount Derivative liability Short term note and liabilities Total current liabilities Total Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Preferred stock, authorized, 20,000,000 shares, $.001 par value, 0 shares issued and outstanding Common stock, authorized 400,000,000 shares, $.001 par value, 165,856,760 and 142,352,406 issued and outstanding Shares to be issued Additional paid in capital Accumulated deficit Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Executive compensation General and administrative Professional fees Total Operating Expenses Loss from Operations OTHER INCOME (EXPENSE) Foreign exchange rate Gain (loss) on derivative liability Gain (loss) on extinguishment of debt Interest expense Net Income (Loss) before Income Taxes Income tax expense Net Income (Loss) Earnings (loss) per common share Basic Diluted Weighted average shares outstanding Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activies Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Contributed services Shares issued for consulting services Shares issued for contribution Options expense Amortization of debt discount to interest expense Amortization of prepaids Foreign currency exchange Gain on derivative liability Loss on extinguishment of debt Changes in operating assets and liabilities Prepaid expense Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Net cash used in operating activities Cash flows from investing activities Purchase of equipment Net cash used in investing activities Cash flows from financing activities Issuance of convertible debt Payment on debt Debt issuance costs Net cash provided by financing activities Net increase in cash Cash, beginning of period Cash, end of period Supplemental Information: Cash paid for: Taxes Interest Expense Non cash items: Warrants issued with debt Derivative liability and debt discount issued with new notes Shares issued for debt conversion Exercise of warrants Shares issued for extinguishment of accounts payable Shares issued for prepaids Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Accounting Policies [Abstract] Summary of Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Non-Convertible Notes Payable Convertible Notes Payable Equity [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Valuation Subsequent Events [Abstract] EX-101.PRE 12 ewll-20180630_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 13, 2018
Document And Entity Information
Entity Registrant Name	eWELLNESS HEALTHCARE Corp
Entity Central Index Key	0001550020
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		174,114,818
Trading Symbol	EWLL
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 9,083	$ 6,882
Prepaid Expenses	171,570	179,827
Total current assets	180,653	186,709
Property & equipment, net	8,439	5,021
Intangible assets, net	12,477	13,954
TOTAL ASSETS	201,569	205,684
CURRENT LIABILITIES
Accounts payable and accrued expenses	316,025	345,956
Accounts payable - related party	564,752	351,511
Accrued expenses - related party	218,000	210,828
Accrued compensation	1,120,960	1,071,369
Contingent liability	90,000	90,000
Convertible debt, net of discount	669,650	444,680
Derivative liability	376,951	1,140,578
Short term note and liabilities		180,051
Total current liabilities	3,356,338	3,834,973
Total Liabilities	3,356,338	3,834,973
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, authorized, 20,000,000 shares, $.001 par value, 0 shares issued and outstanding
Common stock, authorized 400,000,000 shares, $.001 par value, 165,856,760 and 142,352,406 issued and outstanding	165,857	142,352
Shares to be issued	14,800
Additional paid in capital	15,221,625	13,178,131
Accumulated deficit	(18,557,051)	(16,949,772)
Total Stockholders' Deficit	(3,154,769)	(3,629,289)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 201,569	$ 205,684

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	400,000,000	400,000,000
Common stock, par value	$ .001	$ .001
Common stock, shares issued	165,856,760	142,352,406
Common stock, shares outstanding	165,856,760	142,352,406

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
OPERATING EXPENSES
Executive compensation	$ 102,000	$ 102,000	$ 204,000	$ 204,000
General and administrative	290,748	234,841	487,438	418,178
Professional fees	440,326	612,721	952,851	1,316,732
Total Operating Expenses	833,074	949,562	1,644,289	1,938,910
Loss from Operations	(833,074)	(949,562)	(1,644,289)	(1,938,910)
OTHER INCOME (EXPENSE)
Foreign exchange rate	692	24,691	8,091	37,404
Gain (loss) on derivative liability	(116,275)	(843,038)	393,477	4,399,596
Gain (loss) on extinguishment of debt	(43,131)		(43,131)
Interest expense	(139,891)	(120,567)	(319,800)	(223,920)
Net Income (Loss) before Income Taxes	(1,131,679)	(1,888,476)	(1,605,652)	2,274,170
Income tax expense	(1,627)		(1,627)	(800)
Net Income (Loss)	$ (1,133,306)	$ (1,888,476)	$ (1,607,279)	$ 2,273,370
Earnings (loss) per common share
Basic	$ (0.01)	$ (0.02)	$ (0.01)	$ 0.03
Diluted	$ (0.01)	$ (0.02)	$ (0.01)	$ 0.03
Weighted average shares outstanding
Basic	156,216,150	105,459,623	151,077,846	82,876,801
Diluted	156,216,150	105,459,623	151,077,846	85,564,942

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activies
Net income (loss)	$ (1,607,279)	$ 2,273,370
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	2,996	2,512
Contributed services	111,000	109,500
Shares issued for consulting services	250,700	94,150
Shares issued for contribution	70,000
Options expense	217,188	217,188
Amortization of debt discount to interest expense	239,710	176,296
Amortization of prepaids	126,992	789,994
Foreign currency exchange	8,091
Gain on derivative liability	(393,477)	(4,399,596)
Loss on extinguishment of debt	43,131
Changes in operating assets and liabilities
Prepaid expense	90,265	(43,752)
Accounts payable and accrued expenses	38,572	22,583
Accounts payable - related party	213,241	17,169
Accrued expenses - related party	7,172	77,441
Accrued compensation	49,591	47,666
Net cash used in operating activities	(532,107)	(615,479)
Cash flows from investing activities
Purchase of equipment	(4,937)	(2,910)
Net cash used in investing activities	(4,937)	(2,910)
Cash flows from financing activities
Issuance of convertible debt	594,800	776,500
Payment on debt	(1,005)
Debt issuance costs	(54,550)	(110,550)
Net cash provided by financing activities	539,245	665,950
Net increase in cash	2,201	47,561
Cash, beginning of period	6,882	13,995
Cash, end of period	9,083	61,556
Supplemental Information:
Taxes	1,267	800
Interest Expense
Non cash items:
Warrants issued with debt		86,730
Derivative liability and debt discount issued with new notes	219,526	155,885
Shares issued for debt conversion	569,999	3,220,392
Exercise of warrants		109,978
Shares issued for extinguishment of accounts payable		309,000
Shares issued for prepaids	$ 209,000	$ 278,500

XML 18 R6.htm IDEA: XBRL DOCUMENT

The Company

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

Note 1. The Company

The Company and Nature of Business

XML 19 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Going Concern

Fair Value of Financial Instruments

As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	376,951	$	-	$	-	$	376,951
Total Liabilities measured at fair value	$	376,951	$	-	$	-	$	376,951

As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	1,140,578	$	-	$	-	$	1,140,578
Total Liabilities measured at fair value	$	1,140,578	$	-	$	-	$	1,140,578

XML 20 R8.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2018

Related Party Transactions

Note 3. Related Party Transactions

XML 21 R9.htm IDEA: XBRL DOCUMENT

Non-Convertible Notes Payable

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Non-Convertible Notes Payable

Note 4. Non-Convertible Notes Payable

	1.	The Company will issue 2,709,444 shares of commons stock that is immediately tradeable under Securities and Exchange Commission Rule 144, but subject to a daily trading limit of 25,000 shares per day;
	2.	The Company will issue 1,290,556 shares of common stock that shall be subject to a 180-day holding period and are also subject to a daily trading limit of 25,000 shares per day;
	3.	The holder of the note payable shall bear all fees and expenses, including attorneys’ fees, associated with the transfer and trading of the Company’s shares;
	4.	Beyond issuing the shares noted above, the Company shall not take any additional action that would cause the note holder to incur tax consequence from the transfer or would affect the note holder’s tax consequences in any way.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Convertible Notes Payable

Note 5. Convertible Notes Payable

XML 23 R11.htm IDEA: XBRL DOCUMENT

Equity Transactions

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Equity Transactions

Note 6. Equity Transactions

Common Stock

During the six months ended June 30, 2018, the Company issued 2,550,000 shares of common stock for marketing and consulting services valued at $235,900.

Stock Options

The following is a summary of the status of all Company’s stock options as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of Stock		Average Exercise		Remaining		Intrinsic
	Options		Price		Life (yrs)		Value
Outstanding at December 31, 2017		20,000,000	$	0.26		1.9	$	-
Granted		-		-
Exercised		-		-
Cancelled		-		-
Outstanding at June 30, 2018		20,000,000		0.26		1.8	$	-
Options exercisable at June 30, 2018		16,398,958	$	0.28		1.8	$	-

The Company recognized stock option expense of $217,188 and $217,288 for the six months ended June 30, 2018 and 2017.

Warrants

In February 2017, the Company authorized the issuance of 68,750 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $5,932.

In April 2017, the Company authorized the issuance of 1,232,000 warrants that were issued as part of a convertible note. At June 30, 2018 the fair value of the warrants is $106,732.

The following is a summary of the status of the Company’s warrants as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of		Average Exercise		Remaining		Intrinsic
	Warrants		Price		Life (yrs.)		Value
Outstanding at December 31, 2017		8,753,179	$	0.21		2.4	$	0.038
Granted		417,429	$	0.05		1.0		-
Exercised		-		-		-		-
Cancelled		3,217,429	$	0.05		1.0		-
Outstanding at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038
Warrants exercisable at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038

Stock price on the valuation date	$	.0673-.089
Exercise price of warrants	$	.004 and .25
Dividend yield		0.00	%
Years to maturity		3-4
Risk free rate		2.33%-2.68	%
Expected volatility		245.23%-257.73	%

XML 24 R12.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments, Contingencies

Note 7. Commitments, Contingencies

XML 25 R13.htm IDEA: XBRL DOCUMENT

Derivative Valuation

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Valuation

Note 8. Derivative Valuation

During the six months ended June 30, 2018, the Company had the following activity in the derivative liability account:

	Total
Derivative liability at December 31, 2017	$	1,140,578
Addition of new conversion option derivatives		91,283
Extinguishment due to note conversions		(258,823	)
Extinguishment due to note cancellations		(202,610	)
Changes in fair value		(393,477	)
Derivative liability at June 30, 2018	$	376,951

Stock price at valuation date	$	.0725-.089
Exercise price of warrants	$	.004 - .25
Conversion rate of convertible debt	$	.0495 – 0.2000
Risk free interest rate		1.93%-2.68	%
Stock volatility factor		110.9%-257.73	%
Years to Maturity		.08 – 4
Expected dividend yield		None

XML 26 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

Note 9. Subsequent Events

In July 2018, the Company entered into a consulting services agreement with a consultant for one year for a monthly fee of $5,000.

In July 2018, the Company executed an 12% Fixed Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 30, 2019 has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price into which any principal amount and interest (including any default interest) under the notes shall be convertible into shares of common stock shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average VWAP for the ten(10) trading day period ending on the latest compete trading day prior to the conversion date. The Company issued 100,000 shares of common stock valued at $8,000 upon execution of this note.

During the month of July to the filling of this report, the Company has issued 700,000 shares of common stock for consulting services valued at $52,775.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Going Concern

Fair Value of Financial Instruments

As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	376,951	$	-	$	-	$	376,951
Total Liabilities measured at fair value	$	376,951	$	-	$	-	$	376,951

As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	1,140,578	$	-	$	-	$	1,140,578
Total Liabilities measured at fair value	$	1,140,578	$	-	$	-	$	1,140,578

XML 28 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Assets and Liabilities Fair Value Recurring Basis

As of June 30, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	376,951	$	-	$	-	$	376,951
Total Liabilities measured at fair value	$	376,951	$	-	$	-	$	376,951

As of December 31, 2017, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative Liability	$	1,140,578	$	-	$	-	$	1,140,578
Total Liabilities measured at fair value	$	1,140,578	$	-	$	-	$	1,140,578

XML 29 R17.htm IDEA: XBRL DOCUMENT

Equity Transactions (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of Stock		Average Exercise		Remaining		Intrinsic
	Options		Price		Life (yrs)		Value
Outstanding at December 31, 2017		20,000,000	$	0.26		1.9	$	-
Granted		-		-
Exercised		-		-
Cancelled		-		-
Outstanding at June 30, 2018		20,000,000		0.26		1.8	$	-
Options exercisable at June 30, 2018		16,398,958	$	0.28		1.8	$	-

Schedule of Warrant Activity

The following is a summary of the status of the Company’s warrants as of June 30, 2018 and changes during the six months ended on that date:

			Weighted
	Number of		Average Exercise		Remaining		Intrinsic
	Warrants		Price		Life (yrs.)		Value
Outstanding at December 31, 2017		8,753,179	$	0.21		2.4	$	0.038
Granted		417,429	$	0.05		1.0		-
Exercised		-		-		-		-
Cancelled		3,217,429	$	0.05		1.0		-
Outstanding at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038
Warrants exercisable at June 30, 2018		5,953,179	$	0.31		2.4	$	0.038

Schedule of Valuation Assumptions

The assumptions used in the Black Scholes valuation of the date of issuance are as follows:

Stock price on the valuation date	$	.0673-.089
Exercise price of warrants	$	.004 and .25
Dividend yield		0.00	%
Years to maturity		3-4
Risk free rate		2.33%-2.68	%
Expected volatility		245.23%-257.73	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Derivative Valuation (Tables)

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liability

During the six months ended June 30, 2018, the Company had the following activity in the derivative liability account:

	Total
Derivative liability at December 31, 2017	$	1,140,578
Addition of new conversion option derivatives		91,283
Extinguishment due to note conversions		(258,823	)
Extinguishment due to note cancellations		(202,610	)
Changes in fair value		(393,477	)
Derivative liability at June 30, 2018	$	376,951

Schedule of Assumptions Used Black Scholes Valuation of Derivative

The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

Stock price at valuation date	$	.0725-.089
Exercise price of warrants	$	.004 - .25
Conversion rate of convertible debt	$	.0495 – 0.2000
Risk free interest rate		1.93%-2.68	%
Stock volatility factor		110.9%-257.73	%
Years to Maturity		.08 – 4
Expected dividend yield		None

XML 31 R19.htm IDEA: XBRL DOCUMENT

The Company (Details Narrative)	6 Months Ended
The Company (Details Narrative)	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Physical therapy investment, description	The Company's PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Accumulated deficit	$ 18,557,051	$ 16,949,772

XML 33 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Derivative Liability	$ 376,951	$ 1,140,578
Total liabilities measure at fair value	376,951	1,140,578
Level 1 [Member]
Derivative Liability
Total liabilities measure at fair value
Level 2 [Member]
Derivative Liability
Total liabilities measure at fair value
Level 3 [Member]
Derivative Liability	376,951	1,140,578
Total liabilities measure at fair value	$ 376,951	$ 1,140,578

XML 34 R22.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)			6 Months Ended	12 Months Ended
	Apr. 02, 2017	Nov. 30, 2016	Jun. 30, 2018	Dec. 31, 2017
Accounts payable-related party			$ 1,920	$ 700
Percentage of patient insurance reimbursements received			75.00%
Rent expense			$ 500
Accrued directors' fees			218,000	205,000
Accrued deferred compensation			1,120,960	1,071,369
Officers [Member]
Due to related party			0	$ 5,828
Former Secretary-Treasurer and CFO [Member]
Amount paid by related parties			10,430
Programming Company [Member]
Percentage of patient insurance reimbursements received		40.00%
Monthly base fee		$ 100,000
Fee payable per month		50,000
Amount indebted		$ 225,000
Shares issued for services, shares	25,280,899
Shares issued price per share	$ 0.0089
Due to related party			$ 562,832

XML 35 R23.htm IDEA: XBRL DOCUMENT

Non-Convertible Notes Payable (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
	Jun. 20, 2018	Feb. 28, 2017	Jun. 30, 2018	Jun. 30, 2017
Number of common stock shares issued	4,000,000
Common Stock One [Member]
Number of common stock shares issued	2,709,444
Number of shares issued in transaction	25,000
Common Stock Two [Member]
Number of common stock shares issued	1,290,556
Number of shares issued in transaction	25,000
Note Holder [Member]
Promissory notes payable
Principal payment of promissory note		$ 75,500
Accrued interest
Interest expense note			$ 15,183	$ 16,071
Non-Convertible Notes Payable [Member]
Promissory notes payable		$ 75,500
Promissory note payable description		The Company is indebted to the note holder a promissory note stemming from four loans to the Company during the last 20 months amounting to $75,500 in total original principal bearing interest at 12% per annum
Debt instrument interest rate		12.00%
Principal payment of promissory note		$ 45,202
Debt default remaining balance		$ 253,877
Debt effective rate percentage		70.00%

XML 36 R24.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Narrative)	1 Months Ended					6 Months Ended
Convertible Notes Payable (Details Narrative)	Jun. 30, 2018 USD ($) Integer $ / shares	May 30, 2018 USD ($) Integer $ / shares	Mar. 31, 2018 USD ($) Integer $ / shares	Feb. 28, 2018 USD ($) Integer $ / shares	Jan. 31, 2018 USD ($) Integer $ / shares	Jun. 30, 2018 USD ($) $ / shares
8% Fixed Convertible Promissory Note [Member]
Debt face amount		$ 125,000			$ 110,000
Debt maturity date		May 10, 2019			Oct. 12, 2018
Original issue discount		$ 3,750			$ 10,000
Debt conversion price per share \| $ / shares					$ 0.20
Convertible debt percentage		72.00%			65.00%
Number of trading days \| Integer		10			15
Interest expense debt		$ 1,370				$ 4,099
8% Fixed Convertible Promissory Note [Member] \| Maximum [Member]
Debt face amount	$ 80,500					$ 80,500
8% Fixed Convertible Promissory Note [Member] \| Investor [Member] \| Minimum [Member]
Original issue discount percentage						10.00%
8% Fixed Convertible Promissory Note [Member] \| Investor [Member] \| Maximum [Member]
Original issue discount percentage						15.00%
12% Fixed Convertible Promissory Note [Member]
Debt face amount		$ 51,750			$ 91,300
Debt maturity date		Mar. 01, 2019			Oct. 30, 2018
Original issue discount		$ 6,750			$ 8,300
Debt conversion price per share \| $ / shares		$ 0.20			$ 0.20
Convertible debt percentage		75.00%			75.00%
Number of trading days \| Integer		10			10
Interest expense debt		$ 612				$ 5,073
12% Fixed Convertible Promissory Note One [Member]
Debt face amount				$ 63,800
Debt maturity date				Nov. 30, 2018
Original issue discount				$ 5,800
Debt conversion price per share \| $ / shares				$ 0.20
Convertible debt percentage				75.00%
Number of trading days \| Integer				10
Interest expense debt						2,853
8% Fixed Convertible Promissory Note One [Member]
Debt face amount			$ 77,000
Debt maturity date			Dec. 05, 2018
Original issue discount			$ 7,000
Debt conversion price per share \| $ / shares			$ 0.20
Convertible debt percentage			75.00%
Number of trading days \| Integer			20
Interest expense debt						1,975
12% Fixed Convertible Promissory Note Two [Member]
Debt face amount	$ 72,450					$ 72,450
Debt maturity date	Dec. 30, 2018
Original issue discount	$ 9,450
Debt conversion price per share \| $ / shares	$ 0.20					$ 0.20
Convertible debt percentage	75.00%
Number of trading days \| Integer	10
Interest expense debt						$ 2,453

XML 37 R25.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details Narrative) - USD ($)		1 Months Ended					6 Months Ended
Equity Transactions (Details Narrative) - USD ($)	Jun. 20, 2018	Jun. 30, 2018	Mar. 30, 2018	Jan. 31, 2018	Apr. 30, 2017	Feb. 28, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Shares issued during period for compensation, shares
Debt converted into common stock shares issued							569,998	3,220,392
Converted debt into shares amount							$ 569,999	$ 3,220,392
Number of common stock shares issued during the period	4,000,000
Common stock par value		$ .001					$ .001		$ .001
Stock option expense							$ 217,188	$ 217,188
Warrant [Member]
Fair value of warrants							5,932
Warrant One [Member]
Fair value of warrants							$ 106,732
Convertible Note [Member] \| Warrant [Member]
Number of warrant issued in connection with convertible note						68,750
Convertible Note [Member] \| Warrant One [Member]
Number of warrant issued in connection with convertible note					1,232,000
Maximum [Member]
Warrant original exercise price		$ .25					$ .25
United States Federal District Count [Member]
Debt converted into common stock shares issued							4,000,000
Converted debt into shares amount							$ 236,868
Accrued interest		$ 56,817					$ 56,817
Consulting and Marketing Services [Member]
Shares issued during period for consulting services, shares							2,550,000
Shares issued during period for consulting services, value							$ 235,900
Common Shares [Member]
Shares issued during period for consulting services, shares							200,000
Shares issued during period for consulting services, value							$ 14,800
Debt converted into common stock shares issued							13,654,354
Converted debt into shares amount							$ 569,998
Accrued interest		$ 19,776					$ 19,776
Consulting Agreement [Member]
Number of common stock shares issued during the period		125,000
Consulting Agreement [Member] \| July 2018 [Member]
Number of common stock shares issued during the period		1,500,000
Consulting Agreement [Member] \| Common Shares [Member]
Number of common stock shares issued during the period		1,500,000
Number of common stock shares issued		$ 105,000
Board of Directors [Member]
Unexercised warrants granted		417,429					417,429
Warrant expiration date description		The original expiration date of April 9, 2018 is extended to April 9, 2019.
Warrant original exercise price		$ 0.35					$ 0.35
Warrant reduced exercise price		$ .05					.05
Board of Directors [Member] \| Equity Incentive Plan [Member]
Number of common stock shares issued during the period				20,000,000
Board of Directors [Member] \| Advisory Agreement [Member]
Shares issued during period for compensation, shares				800,000
Shares issued during period for compensation, value				$ 104,000
Investor [Member] \| Equity Purchase Agreement [Member]
Number of restricted common stock issued, shares		1,000,000
Number of restricted common stock issued		$ 70,000
Investor [Member] \| Equity Purchase Agreement [Member] \| Maximum [Member]
Number of common stock shares issued during the period		1,500,000
Common stock par value		$ 0.001					$ 0.001
Officers, Directors and Consultants [Member] \| Equity Incentive Plan [Member]
Number of common stock shares issued during the period				17,400,000

XML 38 R26.htm IDEA: XBRL DOCUMENT

Equity Transactions - Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2018 USD ($) $ / shares shares
Equity [Abstract]
Number of Stock Options Outstanding, Beginning Balance \| shares	20,000,000
Number of Stock Options Outstanding, Granted \| shares
Number of Stock Options Outstanding, Exercised \| shares
Number of Stock Options Outstanding, Cancelled \| shares
Number of Stock Options Outstanding, Ending Balance \| shares	20,000,000
Number of Stock Options Exercisable, Ending Balance \| shares	16,398,958
Weighted Average Exercise Price Outstanding, Beginning \| $ / shares	$ 0.26
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price Outstanding, Ending \| $ / shares	0.26
Weighted Average Exercise Price Options Exercisable, Ending Balance \| $ / shares	$ 0.28
Remaining Life (yrs) Outstanding, Beginning	1 year 10 months 25 days
Remaining Life (yrs), Outstanding, Ending	1 year 9 months 18 days
Remaining Life (yrs) Options Exercisable, Ending Balance	1 year 9 months 18 days
Intrinsic Value Outstanding, Beginning Balance \| $
Intrinsic Value, Ending Balance \| $
Intrinsic Value Options Exercisable, Ending Balance \| $

XML 39 R27.htm IDEA: XBRL DOCUMENT

Equity Transactions - Schedule of Warrant Activity (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Number of Warrants Outstanding, Beginning Balance \| shares	8,753,179
Number of Warrants Granted \| shares	417,429
Number of Warrants Exercised \| shares
Number of Warrants Cancelled \| shares	3,217,429
Number of Warrants Outstanding, Ending Balance \| shares	5,953,179
Number of Warrants exercisable, Ending balance \| shares	5,953,179
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 0.21
Weighted Average Exercise Price, Warrants Granted	0.05
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled	0.05
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance	0.31
Weighted Average Exercise Price Exercisable, Ending	$ 0.31
Remaining Life (yrs) Outstanding, Beginning	2 years 4 months 24 days
Remaining Life (yrs), Granted	1 year
Remaining Life (yrs), Cancelled	1 year
Remaining Life (yrs) Outstanding, Ending	2 years 4 months 24 days
Remaining Life (yrs) Exercisable, Ending	2 years 4 months 24 days
Intrinsic Value Outstanding, Beginning Balance	$ 0.038
Intrinsic Value, Ending Balance	0.038
Intrinsic Value Exercisable, Ending Balance	$ 0.038

XML 40 R28.htm IDEA: XBRL DOCUMENT

Equity Transactions - Schedule of Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares
Dividend yield	0.00%
Minimum [Member]
Stock price on the valuation date	$ 0.0673
Exercise price of warrants	$ .004
Years to maturity	3 years
Risk free rate	2.33%
Expected volatility	245.23%
Maximum [Member]
Stock price on the valuation date	$ 0.089
Exercise price of warrants	$ .25
Years to maturity	4 years
Risk free rate	2.68%
Expected volatility	257.73%

XML 41 R29.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Percentage of returned funds	90.00%
Percentage of funds proceed	10.00%
Percentage of required funds	90.00%
Escrowed funds	$ 100,000
Proceeds from escrowed funds	10,000
Return of escrowed funds	90,000
Contingent liability	$ 90,000	$ 90,000
Escrow Trust [Member]
Percentage of subscription proceeds	10.00%
Trust account balance	$ 90,000

XML 42 R30.htm IDEA: XBRL DOCUMENT

Derivative Valuation (Details Narrative) - USD ($)	6 Months Ended
Derivative Valuation (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amortized of the debt discount	$ 239,710	$ 176,296
Derivative liability	$ 376,951		$ 1,140,578

XML 43 R31.htm IDEA: XBRL DOCUMENT

Derivative Valuation - Schedule of Derivative Liability (Details)	6 Months Ended
	Jun. 30, 2018 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liability, beginning balance	$ 1,140,578
Addition of new conversion option derivatives	91,283
Extinguishment due to note conversions	(258,823)
Extinguishment due to note cancellations	(202,610)
Changes in fair value	(393,477)
Derivative liability, ending balance	$ 376,951

XML 44 R32.htm IDEA: XBRL DOCUMENT

Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares
Minimum [Member]
Stock price at valuation date	$ 0.0673
Maximum [Member]
Stock price at valuation date	$ 0.089
Derivative Liability [Member] \| Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0.00%
Derivative Liability [Member] \| Minimum [Member]
Stock price at valuation date	$ 0.725
Conversion rate of convertible debt	0.0495
Derivative Liability [Member] \| Minimum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, per share	$ 0.004
Derivative Liability [Member] \| Minimum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	1.93%
Derivative Liability [Member] \| Minimum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	110.90%
Derivative Liability [Member] \| Minimum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	29 days
Derivative Liability [Member] \| Maximum [Member]
Stock price at valuation date	$ 0.89
Conversion rate of convertible debt	0.2000
Derivative Liability [Member] \| Maximum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, per share	$ 0.25
Derivative Liability [Member] \| Maximum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	2.68%
Derivative Liability [Member] \| Maximum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	257.73%
Derivative Liability [Member] \| Maximum [Member] \| Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	4 years

XML 45 R33.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)		1 Months Ended			3 Months Ended		6 Months Ended
Subsequent Events (Details Narrative)	Jun. 20, 2018 shares	Jul. 31, 2018 USD ($) Integer $ / shares shares	Jun. 30, 2018 USD ($) Integer $ / shares	Feb. 28, 2018 USD ($) Integer $ / shares	Jun. 30, 2018 USD ($) $ / shares	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) $ / shares	Jun. 30, 2017 USD ($)
Stock issued during period, shares \| shares	4,000,000
Consulting fees					$ 440,326	$ 612,721	$ 952,851	$ 1,316,732
Subsequent Event [Member]
Stock issued for consulting services, shares \| shares		700,000
Stock issued for consulting services, value		$ 52,775
Stock issued for conversion of convertible debt, shares \| shares		7,408,058
Stock issued for conversion of convertible debt, value		$ 369,843
Accrued interest		138,983
Subsequent Event [Member] \| Consulting Services Agreement [Member]
Consulting fees		5,000
12% Fixed Convertible Promissory Note Two [Member]
Debt face amount			$ 72,450		$ 72,450		$ 72,450
Debt maturity date			Dec. 30, 2018
Original issue discount			$ 9,450
Debt conversion price per share \| $ / shares			$ 0.20		$ 0.20		$ 0.20
Convertible debt percentage			75.00%
Number of trading days \| Integer			10
12% Fixed Convertible Promissory Note Two [Member] \| Subsequent Event [Member]
Debt face amount		$ 56,500
Debt maturity date		Apr. 17, 2019
Original issue discount		$ 6,500
Debt conversion price per share \| $ / shares		$ 0.21
Convertible debt percentage		75.00%
Number of trading days \| Integer		30
3% Fixed Convertible Promissory Note [Member] \| Subsequent Event [Member]
Convertible debt percentage		75.00%
Number of trading days \| Integer		20
Proceeds from debt		$ 60,000
3% Fixed Convertible Promissory Note [Member] \| Subsequent Event [Member] \| Tranche One [Member]
Debt face amount		180,000
Original issue discount		10,000
3% Fixed Convertible Promissory Note [Member] \| Subsequent Event [Member] \| Tranche Two [Member]
Debt face amount		180,000
Original issue discount		10,000
3% Fixed Convertible Promissory Note [Member] \| Subsequent Event [Member] \| Tranche Three [Member]
Debt face amount		180,000
Original issue discount		10,000
12% Fixed Convertible Promissory Note One [Member]
Debt face amount				$ 63,800
Debt maturity date				Nov. 30, 2018
Original issue discount				$ 5,800
Debt conversion price per share \| $ / shares				$ 0.20
Convertible debt percentage				75.00%
Number of trading days \| Integer				10
12% Fixed Convertible Promissory Note One [Member] \| Subsequent Event [Member]
Debt face amount		$ 28,250
Debt maturity date		Apr. 17, 2019
Original issue discount		$ 3,250
Debt conversion price per share \| $ / shares		$ 0.21
Convertible debt percentage		75.00%
Number of trading days \| Integer		30
Stock issued during period, shares \| shares		50,000
Stock issued during period, value		$ 4,000
12% Fixed Convertible Promissory Note Two [Member] \| Subsequent Event [Member]
Debt face amount		$ 56,500
Debt maturity date		Apr. 30, 2019
Original issue discount		$ 6,500
Debt conversion price per share \| $ / shares		$ 0.20
Convertible debt percentage		75.00%
Number of trading days \| Integer		10
Stock issued during period, shares \| shares		100,000
Stock issued during period, value		$ 8,000

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 110 211 1 false 46 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ewellnesshealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://ewellnesshealth.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://ewellnesshealth.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://ewellnesshealth.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://ewellnesshealth.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - The Company Sheet http://ewellnesshealth.com/role/Company The Company Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Related Party Transactions Sheet http://ewellnesshealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Non-Convertible Notes Payable Notes http://ewellnesshealth.com/role/Non-convertibleNotesPayable Non-Convertible Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - Convertible Notes Payable Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 10 false false R11.htm 00000011 - Disclosure - Equity Transactions Sheet http://ewellnesshealth.com/role/EquityTransactions Equity Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Commitments, Contingencies Sheet http://ewellnesshealth.com/role/CommitmentsContingencies Commitments, Contingencies Notes 12 false false R13.htm 00000013 - Disclosure - Derivative Valuation Sheet http://ewellnesshealth.com/role/DerivativeValuation Derivative Valuation Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://ewellnesshealth.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Equity Transactions (Tables) Sheet http://ewellnesshealth.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://ewellnesshealth.com/role/EquityTransactions 17 false false R18.htm 00000018 - Disclosure - Derivative Valuation (Tables) Sheet http://ewellnesshealth.com/role/DerivativeValuationTables Derivative Valuation (Tables) Tables http://ewellnesshealth.com/role/DerivativeValuation 18 false false R19.htm 00000019 - Disclosure - The Company (Details Narrative) Sheet http://ewellnesshealth.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://ewellnesshealth.com/role/Company 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies-SummaryOfAssetsAndLiabilitiesFairValueRecurringBasisDetails Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) Details 21 false false R22.htm 00000022 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ewellnesshealth.com/role/RelatedPartyTransactions 22 false false R23.htm 00000023 - Disclosure - Non-Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/Non-convertibleNotesPayableDetailsNarrative Non-Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/Non-convertibleNotesPayable 23 false false R24.htm 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/ConvertibleNotesPayable 24 false false R25.htm 00000025 - Disclosure - Equity Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://ewellnesshealth.com/role/EquityTransactionsTables 25 false false R26.htm 00000026 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-SummaryOfStockOptionsActivityDetails Equity Transactions - Summary of Stock Options Activity (Details) Details 26 false false R27.htm 00000027 - Disclosure - Equity Transactions - Schedule of Warrant Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-ScheduleOfWarrantActivityDetails Equity Transactions - Schedule of Warrant Activity (Details) Details 27 false false R28.htm 00000028 - Disclosure - Equity Transactions - Schedule of Valuation Assumptions (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-ScheduleOfValuationAssumptionsDetails Equity Transactions - Schedule of Valuation Assumptions (Details) Details 28 false false R29.htm 00000029 - Disclosure - Commitments, Contingencies (Details Narrative) Sheet http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative Commitments, Contingencies (Details Narrative) Details http://ewellnesshealth.com/role/CommitmentsContingencies 29 false false R30.htm 00000030 - Disclosure - Derivative Valuation (Details Narrative) Sheet http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative Derivative Valuation (Details Narrative) Details http://ewellnesshealth.com/role/DerivativeValuationTables 30 false false R31.htm 00000031 - Disclosure - Derivative Valuation - Schedule of Derivative Liability (Details) Sheet http://ewellnesshealth.com/role/DerivativeValuation-ScheduleOfDerivativeLiabilityDetails Derivative Valuation - Schedule of Derivative Liability (Details) Details 31 false false R32.htm 00000032 - Disclosure - Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Sheet http://ewellnesshealth.com/role/DerivativeValuation-ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Details 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ewellnesshealth.com/role/SubsequentEvents 33 false false All Reports Book All Reports ewll-20180630.xml ewll-20180630.xsd ewll-20180630_cal.xml ewll-20180630_def.xml ewll-20180630_lab.xml ewll-20180630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 52 0001493152-18-011665-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-011665-xbrl.zip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end